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Abstract 
As patients begin to receive more oral chemotherapies in the place of the traditional 
parenteral therapies, the responsibility for treatment falls on the shoulders of patients and 
their caregivers. The responsibility for the “five rights” of medication administration, 
which include the- right drug, right dose, right time, right route, and right patient are 
being transferred to patients and care givers. This places patients at risk for medications 
errors. Patients and care providers assume responsibility for medication administration, 
often with little or no healthcare education. As the number of patients being prescribed 
chemotherapies continues to increase, an emphasis on education as well as adherence to 
therapy should be emphasized. Multiple barriers exist, that negatively affect a people’s 
ability to adhere with prescribed treatment. A systematic review was conducted to 
identify the most prevalent barriers to nonadherence in this patient population. The 
Preferred Reporting Items for Systematic Reviews (PRISMA) checklist and flowchart 
were utilized to extrapolate, analyze, and synthesize the date. Common themes were 
identified and organized into three main categories: patient-related factors, system-related 
factors, and nurse and provider-related factors. The most prevalent were analyzed in 
further detail which revealed there were multi-factorial causes of nonadherence to oral 
chemotherapies. Under the patient-related heading, adverse effects and toxicities as well 
as forgetfulness were seen most commonly in the literature. Within the theme of system-
related both regimen complexity and financial causes were found, whereas under nurse 
and provider-related patient education and frequency and length of follow up were most 
common. The advanced practice nurse (APN) is in the prime position to help counter-act 
these barriers to adherence. This systematic review served to help identify common 
causes of nonadherence to patients’ oral chemotherapeutic agents as prescribed. 
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ORAL CHEMOTHERAPY, A TOUGH PILL TO SWALLOW:  
A SYSTEMATIC REVIEW 
Background/Statement of the Problem 
It is estimated that approximately 25-30% of all chemotherapeutic agents 
currently undergoing clinical trials are now by oral route of administration, and this 
number is expected to grow (Tipton, 2015). While oral therapies are often more 
convenient for patients, there are several important factors regarding adherence or 
compliance with treatment that should be taken into consideration. One exploratory study 
found that the primary population being given oral chemotherapies were older adults, had 
several comorbid conditions, and had advanced stage cancer (Given et al., 2015). Another 
study found similar results: subjects were primarily: women, had on average 2.8 
comorbidities, were diagnosed with late stage cancer, and had no caregivers at home 
(Wong, Bounthavong, Nguyen, Bechtoldt, & Hernandez, 2014). All of these factors 
increase the potential for non-adherence to oral chemotherapies placing patients at risk 
for poorer outcomes and higher mortalities. It is important to acknowledge these and 
other barriers to compliance with oral chemotherapy regimens so that healthcare 
providers are better able to mitigate them. These include such factors as belief in efficacy, 
psychological factors, comorbidities, complicated regimen, communication, and 
education as supported in the following literature review. 
Chemotherapy administration is moving out of the infusion centers and hospitals, 
where providers are readily available to monitor and assess them, and into their homes. 
While this change increases patient’s autonomy, freedom, and potentially decreasing 
hospitalizations, exposure to potential infections, and disruptions to patients’ lives, it also 
comes with a tradeoff. Patients are seen by healthcare staff less often and are at higher 
risk for adverse reactions, under or over-adherence, and undertreated side effects. 
This issue is particularly relevant to nurses for several reasons as nonadherence is 
a concept that is very familiar and pertinent to nursing. Nurses are often the staff dealing 
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with the fallout of nonadherence, providing education, advocating for patients, assisting 
with obtaining financial resources, attending to side effects and worsening disease, and 
more. This systematic review will explore issues surrounding nonadherence to oral 
chemotherapy agents and contributing factors in order to change nursing practice around 
these medications. Nurses have the power to positively affect patient outcomes as they 
generally have more contact with patients and their caregivers.  
The review of the literature will be discussed in the next section.  
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Literature Review 
Adherence and Nonadherence Defined 
The World Health Organization (WHO) defines adherence as “the extent to which 
a person’s behavior-taking medication, following a diet, and/or executing lifestyle 
changes corresponds with agreed recommendations from a healthcare provider.”(World 
Health Organization, 2003, p. 17). The NICE guidelines define adherence similarly as the 
level to which the patient’s medication taking practices match the recommendations of 
the physician. This definition however, makes the assumption that there is a mutual 
agreement on the part of both the patient and the physician prescribing (Mantri, 2014). 
 Adherence contrasts with the previously used term compliance in several ways. 
First, the term adherence denotes a mutual agreement with both patient and provider, 
while the term compliance has the connotation of a passive relationship where the patient 
is expected to unquestioningly obey orders and take medications as prescribed (Mitchell, 
2014). Compliance in today’s healthcare system is a term that is much less commonly 
used due to its outdated application in a paternalistic system. It is still commonly used 
however as it applies to the psychiatric population as at times patients who are 
incompetent are treated without the direct consent of the patient themselves for their 
safety (Vuckovich, 2010). Vuckovich refers in her research specifically to those patients 
who are in a state of psychosis, but acknowledges that forced compliance in patients who 
are incompetent is seen in other populations as well, such as those with forms of 
dementia.  
A patient is considered non-adherent if they do not take their medications as 
prescribed due to missing doses, taking too many doses, taking medications at the wrong 
time, or at the wrong dosage (World Health Organization, 2003). Mantri (2014) defines 
nonadherence as when a patient does not take prescribed medications exactly as ordered 
and may be partial or total, intentional or unintentional, and continuous or intermittent in 
nature. She further stated that levels of nonadherence have been reported at 20-70%, but 
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attributes these statistics to varying definitions among researchers, study methods, and 
populations. Mitchell (2014) similarly reported nonadherence rates as ranging from 20-
60%, with the highest concentration of nonadherence occurring with patients with 
chronic conditions.  
There are several types of nonadherence to consider (Gellad, Grenard, 
&McGlynn, 2009). One type is called “non-fulfillment” when a prescriber orders a 
particular medication, but the patient does not have the prescriptions filled. It further 
extends to patients who do have the medication filled, but fail to pick it up and may be 
referred to as “primary nonadherence”. Another type includes “non-persistence” and 
occurs when a patient autonomously decides to cease taking their prescribed medications 
without the direction of a physician. Studies have found that this generally occurs within 
six months of initiating a medication regimen. A third type of nonadherence includes 
“non-conforming” and includes when a patient takes medication in a way that is not 
ordered by their prescriber. This may mean that a patient takes too few or too many 
doses, takes it at the wrong time, wrong dose, or misses doses. As with many aspects of 
healthcare, nonadherence with medication and the severity of repercussions associated 
with it vary based on the type of medication. Taking antibiotics inappropriately can lead 
to severe health consequences such as drug resistant bacteria or recurrent infection, while 
missing a dose of a thyroid medication or vitamin may not have such severe concerns 
(Gellad et al.). 
Nonadherence is not a new phenomenon and certainly not specific to the 
hematology/oncology population. The World Health Organization (WHO, 2013) reported 
that adherence within the hematology/oncology population can be as low as 20%. Issues 
related to adherence have been heavily studied in HIV patients and are being more 
thoroughly examined in other patient populations (WHO).  As patients with all types of 
diseases and conditions are living longer and diagnoses that at one time were a death 
sentence are now a chronic disease, the importance of adherence is crucial. Nonadherence 
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is closely linked with poor patient outcomes, increased resistance to therapies, toxicities, 
adverse events, and side effects and also significantly increases the amount of healthcare 
dollars being spent every year (WHO). The WHO also reported that nonadherence has 
the potential to increase healthcare resources utilized, increase the amount of disability, 
have psychological implications, and substantially decrease quality of life of the patient. 
 
Barriers to Adherence 
Merriam-Webster defines barrier as “something immaterial that impedes or 
separates; an obstacle” as well as “something that makes it difficult for people to 
understand each other” (http://www.merriam-webster.com/dictionary/barrier). The 
application of this term is without exact consensus in the healthcare community literature, 
as the focus tends to be on defining “adherence”. Barriers can be further defined as either 
experienced or perceived as it relates to medication adherence (Duran, George, & Norris, 
2014). The broad umbrella categories of barriers to adherence include socioeconomic, 
healthcare systems, disease, treatment regimen, and patient related. Within these 
categories fall more specific barriers such as language, homelessness, lack of insurance, 
poor communication and follow up with physicians, degree of severity of symptoms, 
regimen complexity, side effects, physical factors, 
psychological/behavioral/developmental factors, and more ("OncoLink," 2014). 
The importance of understanding barriers, both actual and perceived, is crucial in 
order to develop strategies and interventions to help patients cope with or avoid barriers 
(Oncology Nursing Society, 2009).  Practitioners have utilized several different tools to 
help patients increase adherence. One such tool is a calendar which depicts what 
medications a patient needs to take, at what dose, and when to take it. Additionally, many 
drug manufacturers provide financial resources to patients who fall below a certain 
income level. This may mean that a patient may qualify for either partial or complete cost 
assistance and thereby decreasing many financial barriers. Patient education is another 
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powerful way to alleviate barriers to adherence and may include several different key 
pieces of information. Education of patients should extend to family, friends, and 
caregivers whenever possible and should include; side effects, how and when to take their 
medication, written information in the patient’s primary language, and places they can 
obtain additional quality information according the ONS (2009). 
Nonadherence and the General Patient Population 
Minor changes within a patient’s environment can have a strong barrier effect on 
adherence to oral medication. A study (DeBakker, Bouvy, Heerdink, Spreeuwenberg, 
&Vervloet, 2013) performed in the Netherlands on 104 diabetic patients found that even 
the day of the week and the time of day that a patient is instructed to take their 
medications can greatly predict adherence. The authors in this study utilized a real time 
medication monitoring system that recorded the date and time a patient self-administered 
their medications. Adherence was seen to a greater degree (96%) Monday through 
Thursday when ordered to be taken in the morning at. This is in stark contrast to those 
medications patients take in the evening, where adherence dipped down to 33%, 
particularly on Sunday evenings. There was a linear correlation seen with adherence that 
was found to decrease each day of the week, starting on a Monday and ending with the 
lowest adherence on Sunday. Patients were also noted to have more missed doses on 
holidays in addition to weekends. The authors came to the conclusion that any 
interruptions to a one’s daily routine ran the risk of decreasing adherence (DeBakker et 
al.). 
In a review of the literature (Duncan, 2015), complex regimens with multiple 
daily dosing had lower rates of patient adherence in those with chronic obstructive 
pulmonary disease (COPD). Patients who were prescribed inhalers that were to be used 
multiple times within a 24 hour period had poor rates of adherence that tapered off the 
longer they were on therapy. These patients had more complications associated with 
exacerbations, had more hospitalizations, and took longer to recover. Recommendations 
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were to increase self-management of all patients, providing additional teaching and 
pertinent information as well as simplification of regimens when possible (Duncan). 
Some forms of nonadherence are intentional, since some patients consciously 
decide to stop taking their medications or to take them in a way other than prescribed. 
Using Leventhal’s Common-Sense Model of Self-Regulation, Jackson et al. described six 
factors that may play a crucial role in intentional nonadherence with geriatric patients. 
These six aspects include: beliefs about their illness, the risks that they perceive can 
occur from taking the medication, the potential benefits, the relationship between the 
prescribing practitioner and the patient, both physical and mental illnesses, availability of 
financial resources, and issues related to polypharmacy or complex regimens. One 
important factor for healthcare providers to keep in mind is that there is overlap between 
intentional and unintentional nonadherence. Patients who pose an increased risk for this 
overlap are those elderly who are frail and/or socially isolated from others. Historically 
speaking, those who are non-adherent, whether intentional or unintentional, have been 
grouped together by healthcare professionals. Unintentional nonadherence is defined as 
nonadherence that is not a conscious decision, versus intentional which is. The distinction 
between the two is an important one to make because the interventions intended to 
decrease nonadherence vary based on the underlying causes (Jackson, Mukhtar, 
&Weinman, 2014). 
Some patient populations have specific issues related to nonadherence such as 
transplant patients. One would assume that after being given the gift of life via a new 
organ, a patient would be very strictly adherent to prescribed anti-rejection therapies. In 
one systematic review the authors found that as time post-transplant increases, patients 
have less follow up, have their labs drawn less frequently, and become more non-
adherent with treatments, thus leaving them vulnerable to rejection. This systematic 
review focused on varying factors influencing nonadherence following transplantation of 
a solid organ (Morrissey, Flynn, & Lin, 2007).The human cost of nonadherence with 
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transplant patients is large and can lead to graft failure and either chronic or acute 
rejection. Not only is this physically damaging and life threatening for patients, but also 
spiritual, emotional, and psychological as well. According to Morrissey et al. (2007), 
financially, it is costly due to increased hospitalizations, biopsies, more expensive anti-
rejection medications, as well as possible need for additional transplant. 
It is clear that nonadherence in all patient populations can decrease quality of life 
(QOL) and increase healthcare dollars spent each year according to the previously 
mentioned data. The importance of understanding the etiology of nonadherence is crucial 
to decreasing or alleviating it so that patients can have better outcomes with their given 
therapies. While each patient specific population has their own challenges, there is a 
lesson to be learned from each that can be applied to another. By looking at adherence 
among various patient populations, healthcare providers can extrapolate pertinent data 
that can then be applied to other populations, including hematology/oncology. 
Nonadherence and Patients with Comorbidities.  
More often than not, patients with cancer diagnoses have comorbid conditions. In 
a case study by Spoelstra (2015), a 52 year old woman with a diagnosis of chronic 
lymphocytic leukemia (CLL) had a history of diabetes mellitus, chronic obstructive 
pulmonary disease, asthma, urinary tracts infections (UTI), and depression. She was 
prescribed ibrutinib for her CLL. She was subsequently diagnosed with a UTI and placed 
on ciprofloxacin. This patient had severe adverse effects from a drug-drug interaction 
between the two drugs which required medical interventions. This example demonstrates 
how comorbidities increase the risk of adverse drug reactions, confusion related to 
multiple medications, drug-drug interactions, ability to self-manage conditions, increased 
pill burden, and may exacerbate pre-existing conditions (Spoelstra). 
Disease and health factors play an important role in adherence along with other 
factors. At times, the side effects associated with the cancer diagnosis are less severe side 
effects than those associated with comorbid conditions and may lead to poor adherence 
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rates (Irwin & Johnson, 2015). One study found that in a sample of thirty patients, ten 
patients had three or more comorbidities, while thirteen had one to two. The twenty three 
patients all reported that oral treatment for their cancer greatly interfered with their ability 
to manage their other conditions. This study also found that symptoms of chronic 
conditions were often exacerbated by taking oral antineoplastic agents, leading to 
decreased adherence (Given et al., 2015). 
Nonadherence and Patients’ Belief in Efficacy and Psychological Barriers.  
Belief in efficacy was a commonly reported factor among several studies that 
found that if a patient did not feel that the oral chemotherapy was going to be effective, 
they were not adherent to their therapy. Given et al. found this to be the most commonly 
found factor affecting compliance, but also found that if patients had a strong belief in 
efficacy, they may be overly adherent. Over-adherence includes when patients take more 
than the prescribed dose or frequency of their medications, which places them at high risk 
for adverse reactions, side effects, and death.  
A prospective observational study conducted with 99 patients completing self-
reported questionnaires related to adherence in Greece had similar findings and found 
belief in efficacy to be a major barrier to adherence as well (Saratsiotou et al., 2010).  The 
purpose of the study was to study the patterns of treatment to oral chemotherapy. The 
study included having participants completing anonymously a seven page questionnaire 
which included demographic information, information regarding the type of disease they 
had, treatment they were receiving, side effects they were experiencing, as well as issues 
surrounding adherence.  
While patients overall favored the ease of oral administration, 37.5% of 
participants within the study felt oral may not be as effective compared to more 
traditional routes (Saratsiotou et al., 2010). Sixty patients (61%) within the study reported 
a belief that their treatment was going to be effective, eight felt that it would negatively 
affect their disease (8%), and sixteen (16%) felt that it would merely stabilize their 
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cancer. Nonadherence in those who did not believe that their treatment was going to be 
effective was measured as high as 62.5% (n=5) as compared with those who did have a 
belief in efficacy at 16.7% (n=10). 
Characteristics related specifically to both the type of cancer as well as the stage 
at which is it being treated can also weigh heavily on adherence with medication. In a 
literature review with breast cancer patients (Moore, 2010), those who were 
asymptomatic were less likely to be compliant as they perceived less benefit from 
therapy. The purpose of the literature review was to assess the extent of nonadherence of 
oral therapies in patients with breast cancer. Of note, this was a literature review and not 
a systematic review, but looked at a total of 51 research articles spanning between 1993-
2009. In her search, Moore also found that patients who were being treated at earlier 
stages had higher levels of nonadherence as they did not feel as sick as those with later 
stage diseases. Patients who were given treatment with the goal of prevention of either 
recurrence or secondary disease also had lower rates. It is important to point out, 
however, that a majority of studies reviewed were female patients on tamoxifen, which is 
a hormone therapy and not classified as an oral chemotherapy. Belief in efficacy of 
treatment often impacts survivorship, which is important to the longevity of patient’s life 
expectancy and can greatly extend it.  
Certain psychological issues may lead to adherence problems as well. For 
instance, patients who are concerned about disease progression and death may be overly 
adherent, taking more medication than was prescribed by their physician (Lester, 2012). 
Over adherence is just as detrimental as under-adherence and high-risk patients with 
known psychological issues should be assessed prior to initiation of oral therapy. Other 
patients may be over stressed with the added responsibility of having to remember 
additional information at a very stressful time in their lives. Patients can frequently 
become so overwhelmed that they are incapable of retaining information such as dosing, 
frequency, side effects, or when to take their medications (Lester).  
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Nonadherence and Physical or Cognitive Impairment.  
Advanced age plays a significant role in the ability to manage self-administration 
of oral anti-neoplastic agents safely. Older patients may suffer from cognitive and 
memory disorders which affect their ability to absorb information provided to them and 
consequently to comply with prescribed treatment. Forgetting was cited in multiple 
studies as a common cause for poor adherence.  
One United Kingdom study of 43 patients with colon and breast cancer examined 
this aspect of compliance using a self-reported survey (Bhattacharya, Easthall, Small, 
Willoughby, &Waston, 2012). The purpose of this study was to assess factors that 
impacts medicine taking habits of patients on the oral chemotherapeutic capecitabine. 
Participants were recruited during an eight week period in 2009 by their healthcare 
providers after being prescribed capecitabine for either breast or colon cancer. 
Nonadherence was reported by 10 (23%) of the participants over the course of the study. 
Forgetting a dose was the most frequently reported reason for nonadherence to 
capecitabine. Participants reported that forgetting was deemed a more socially acceptable 
form of nonadherence versus intentional behavioral patterns related to poor adherence. 
Reported reasons included simply forgetting to pick up medication from the pharmacy, 
forgetting education provided by healthcare providers on the medication in only verbal 
form, as well as forgetting how and when to take medications (Bhattacharya et al.).  
This older group of patients may also suffer from hearing and visual impairment 
which can alter their ability to absorb education from healthcare workers and self-manage 
at home (Moore, 2010). Visual impairment may cause the patient to inaccurately read 
drug names, labels, doses, frequency, etc. and may cause medication errors (Bhattacharya 
et al., 2012). One case study of a 60 year old patient with brain cancer who mistakenly 
took in one dose the same amount of drug needed in three cycles of chemotherapy 
spanning six weeks. This was due to the fact that her regimen was changed from one 
drug, dosed in one capsule a day; to another medication that was taken as one capsule 
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every three weeks. This patient unfortunately passed away from the error and her 
misunderstanding of her new regimen (Spoelstra, 2015). 
Nonadherence and Communication, Education, and Regimen Complexity.  
Lack of patient education can also be found in the literature and is cited as a 
common cause of unintentional nonadherence with patients. For patients being given 
more traditional intravenous chemotherapy, nurses administering the medication are in an 
excellent position to provide education. Both patients and caregivers are often present at 
the clinic or infusion center for several hours, often over prolonged, periods of time 
which provides healthcare providers ample opportunities to provide information. One 
review of the literature by Hartigan (as cited in Hartigan, 2003) found that patient 
education was considered most valuable at the beginning of treatment, prior to its 
initiation. She further contended that one barrier to adherence is lack of verbal as well as 
written instructions provided to patients and/or their caregivers. This information should 
include; the name of the medication, dose and schedule, how it is to be taken, safety 
concerns, side effects, and how to obtain symptom management.   
The National Health Services in the United Kingdom conducted patient 
satisfaction surveys which looked at various aspects of the patient experience while on 
oral chemotherapy. While patients responded favorably to many questions, several had 
poor responses in regard to aspects of patient education. For example, only 41% were 
offered written information regarding their treatment, only 45% were educated as to 
potential long term side effects, 65% reported having an opportunity to speak with a 
healthcare provider in regards to practical concerns, and 44% reported having the 
opportunity to speak with someone in regards to financial concerns (Quality Health, 
2014).  
Furthermore, the National Comprehensive Cancer Network in their Task Force 
Report on Oral Chemotherapy found that patients are not always forthcoming or 
complete in their communications with their healthcare providers. This can lead to issues 
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when physicians and nurses need to be aware of current medications, diseases, 
conditions, and lifestyle choices so they can be alerted to various contraindications to 
certain treatments. This extends to healthcare providers’ ability to look for and monitor 
side effects of oral chemotherapy in real time if patients do not report them. Delays in 
doing so can result in delayed treatment and increased adverse effects to the patient. One 
program that was assessed in the Task Force Report was the STAR program, where lung 
and gynecologic cancer patients were encouraged to log consistently their side effect 
either at each follow up or from home via an electronic database. In the study with 80 
patients, 43 grade 3 to 4 toxicities were recorded and 7 warranted interventions (National 
Comprehensive Cancer Network [NCCN], 2008). With increased and improved 
communication with healthcare providers, several patients had better outcomes as a direct 
result. It is evident from this data that not only is patient education a concern 
internationally, but that more needs to be done to improve communication and education.  
Chemotherapy regimens are complicated in the traditional inpatient or clinic 
setting and self-administered oral medications are no different. Several studies have cited 
this problem as a reason for decreased adherence among patients. Most regimens contain 
at least two or possibly even more agents with multiple dosing. Additionally, cycling of 
medications is common where patients have on and off days to keep track of. One study 
found that approximately 67% of patients were being treated with complicated regimens. 
This is a source of confusion for patients, especially when they are also on medications 
for other conditions as previously discussed (Given et al., 2015). One example of a 
complex regimen is seen with capecitabine which is commonly used to treat breast and 
colorectal cancers. This drug is to be taken about 30 minutes prior to meals twice daily 
and is a twenty eight day cycle where the patient will take medication for fourteen days 
and then seven off, often concurrently with radiation. If regimens are too complicated for 
patients to comprehend correctly, unintentional nonadherence may result.  
Nonadherence in Hematology/Oncology Patients 
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The number of patients being prescribed oral anti-neoplastic agents for the 
treatment of cancer increases daily (National Comprehensive Cancer Network [NCCN], 
2008). Adherence to these medications has been of concern to healthcare workers in the 
past and continues to be a concern in the present. Unless the factors influencing 
adherence are deciphered, nonadherence will continue to plague future patients as well. It 
is estimated that 125,000 deaths per year can be attributed to non-adherence and is 
accountable for 10-23% of both hospital and skilled nursing home admissions (Moore, 
2010). The World Health Organization estimates that patients on average are only 50% 
adherent with oral medications (World Health Organization, 2003). Nonadherence with 
oral medications is not specific to hematology-oncology patients, but this population 
poses very specific barriers as evidenced by the following literature. 
Nonadherence with Oral Chemotherapies.  
The oral medications used to treat cancers of all types are often thought by many 
patients to be less potent than their counter parts by other routes. However, their side 
effect profiles are often comparable, while some may have even more adverse effects. 
Side effects are generally similar to other chemotherapies and can include mucositis, 
diarrhea, nausea, vomiting, rash, fatigue, and more depending on the specific medication. 
A study conducted in Australia found that only 20% of the 15 participants in a nurse-led 
clinic knew the main side effects associated with their medication(s). It also found that 
only 53.3% of patients knew to report poorly controlled symptoms to their nurse or 
physician, only 40% knew how to correctly use their antiemetic medication, and only 
13.3% how to use their antidiarrheal medications (Griffiths & Pascoe, 2014). 
As noted in Spoelstra et al. (2013), many patients also have comorbidities and the 
treatment for those conditions can lead to increased side effects and toxicities when 
combined with oral anti-neoplastics. Patients may also experience anticipatory side 
effects such as nausea and vomiting which will greatly affect their adherence if not 
properly managed. This information as further supported in a literature review looking at 
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tools to increase adherence within the hematology/oncology population 
(Burhenn&Smudde, 2015). Side effects may also decrease absorption and metabolism of 
drug due to nausea, vomiting, and diarrhea. One study of capecitabine, previously 
described, found that patients even reported non-adherence related to neuropathy caused 
by the medication that prohibited them from getting the medications out of the blister 
packing (Bhattacharya, Easthall, Small, Willoughby, &Waston, 2012). 
Although some anti-cancer drugs have been around for quite some time, emerging 
therapies often remain exorbitant. This can affect a patient’s compliance if they are not 
able to afford the medication as prescribed. Furthermore, even though more 
chemotherapeutic drugs are being covered by insurance benefit plans, due to the 
relatively new nature and costs of several drugs, many patients are restricted to older 
treatments that are covered by their insurance. One study discovered that 25% of 10,508 
patients analyzed from a pharmacy database were paying on average $500 per month in 
co-pays for oral chemotherapies. It also found that up to 50% of this group of patients did 
not return to the physician or for follow up to obtain a different medication within 90 
days. The same study looked at the price per month for different oral chemotherapies and 
revealed that patients with medullary thyroid cancer prescribed either cabozantinib or 
vandetanib costs anywhere from $12,644.28 - $30,690.31 monthly (Bwayo-Weaver, 
Moore, Shah, & Serlemitos-Day, 2013). Another research study found that oral anti-
neoplastics can cost anywhere from $10,000 to $100,000 annually per course of treatment 
for one patient (Rittenberg & Spoelstra, 2015) 
This has lead patients to ration medications or not have prescriptions filled at all 
due to costs. This is seen often in individuals with high deductibles or with incomplete 
coverage and can lead to failure of treatment. Applications for financial assistance are 
commonly long and complicated for most patients who tend to give up and not complete 
them. Issues with prior authorization requirements by insurance companies can also be 
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time-consuming and complicated for healthcare providers and can take several days for 
approval which can lead to a delay in treatment (McMahon &Rudnitzki, 2015). 
It is clear from the above findings within the literature that nonadherence is a 
multi-factorial issue. Problems range from surrounding the healthcare system, to the 
nurse or healthcare provider, to the patient and their caregivers themselves. Given this 
fact, the answer to this concern should also be multi-factorial as well and providers 
should aim to learn from the reasons for nonadherence and apply that knowledge to 
circumventing it whenever possible.  
In the next section, the critical appraisal framework used to guide this systematic 
review will be presented. 
 
 
 
 
 
 
 
 
 
Critical Appraisal Framework 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses, or 
PRISMA, was designed to increase the quality of reporting for both systematic reviews as 
well as meta-analyses. It consists of a 27 item checklist that dictates the minimum 
requirements for evidence- based studies and is utilized as a critical appraisal tool 
(PRISMA, 2009). Items on the checklist include seven major headings: title; abstract; 
introduction; methods; results; discussion; and funding. Within each heading are 
subheadings as well as descriptions defining the expectations for each of the sections. In 
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addition to the checklist, PRISMA also contains a flowchart, which guides researchers in 
the literature search process. The flowchart dictates how to screen and evaluate for 
eligibility within the research based on the study purpose and question.   
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses began 
originally as the Quality of Reporting of Meta-Analysis (QUOROM) statement in 1999 
as there was a call for a standardization and improvement upon the quality of systematic 
reviews as well as meta-analyses (Atlman et al., 2009). It was found that information 
being reported within these studies was of poor quality, poorly presented, and therefore 
of little assistance in establishing quality standards of care for patients. In 2009, the 
statement underwent an overhaul and was recreated as PRISMA. This change was 
prompted as systematic reviews had increased in numbers in this time frame, as 
evidenced by the increase of submissions in the Cochranes Library’s Methodology 
Register (Atlman et al.).  
Additionally, the potential risk for bias within a systematic review or meta-
analysis was becoming widely recognized, requiring additional guidelines to be put in 
place. The changes that were developed were in response to a remaining consistent level 
of poor quality systematic reviews being produced. Additions in the form of the flowchart 
and checklist were made in an effort to increase transparency of reporting even further. 
The flowchart was altered to included the number of articles identified, those included, as 
well as those excluded. The 27 item checklist was created with items deemed necessary 
for transparency of data.  
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
statement itself was developed by 29 consumers, clinicians, review authors, 
methodologists, and medical editors. Items that all members deemed necessary for 
transparent research were all included in the checklist of 27 items. The items on the 
checklist include, but are not limited to the title, objectives (research questions), search 
strategy, study selection, data collection process, summary of evidence, and conclusion. 
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This gives researchers a step by step guide while allowing them to present their research 
in a conclusive and succinct manner (Appendix A). 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses not 
only provides a checklist, but contains a flowchart which assists in obtaining the 
appropriate research. This flowchart also provides a step-by-step set of instructions which 
dictates which articles are retained for the final paper. It also reminds the researcher to 
include an explanation for the exclusion of articles which further increases the 
transparency of the study. It begins with the identification of articles, the screening of 
those articles for appropriateness and eligibility, and ends with the articles to be included 
within the research (PRISMA, 2009)- (Appendix B). 
The world of systematic reviews and meta-analyses continues to evolve and grow 
and so has the format used to evaluate them. At the beginning of 2015, an additional 
group of experts in research assembled to extend the PRISMA statement to look at a 
newer subset of a meta-analysis with greater than two interventions, which is called a 
network meta-analysis (Hutton et al., 2015). This change led to the addition of five more 
items to the checklist for a total of 32 items. All additional 2015 changes can be found 
within the methodology section of the checklist and reflect the goal of decreasing biases 
in reporting.  
For the purpose of this systematic review, the researcher utilized the original 
format of the checklist created in 2009. This was due to the fact that only two variables 
were examined, oral anti-neoplastic agents and barriers to adherence. Both the checklist 
as well as the flowchart were utilized to obtain, evaluate, and report findings in order to 
maintain the completeness and transparency of the research performed. This framework 
was chosen in order to decrease the bias of reporting in the course of this study.  
The methods utilized in this systematic review will be presented next. 
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Method 
Purpose of Study 
The purpose of this systematic review was to identify causes of nonadherence to 
oral chemotherapy on the part of the patient and their caregivers. The question posed 
was: What are the barriers to adherence with oral chemotherapy among the adult 
hematology-oncology patient population identified in recent literature? The outcome 
assessed was the most prevalent barriers to adherence.  
Inclusion and exclusion criteria 
The inclusion criteria included: studies pertaining to subjects 18 years or older, 
studies using only medications classified as oral anti-neoplastics, only those studies 
which are either qualitative or quantitative; and those studies that examined barriers to 
adherence to oral chemotherapy. The exclusion criteria included: non-English articles; 
non-nursing research; hormone therapies; adherence studies that are not related 
specifically to oral anti-neoplastics; chemotherapy administered other than via the oral 
route; and research before 2010. 
Search Strategy 
Utilizing both the PRISMA flowchart (Appendix C) as well as the PRISMA 
checklist (Appendix A), this investigator collected data from Nursing Reference Center 
powered by EBSCO and OVID. The search was conducted using the terms adherence, 
oral anti-neoplatic agents, oral chemotherapy, barriers to adherence, patient compliance, 
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and patient non-compliance with oral chemotherapy. The results yielded in this search 
were applied to the PRISMA flow diagram to assist with article selection. The process 
began with tabulating the number of articles found through the database search as well as 
others located through different sources. After removing any duplicates located, the 
investigator assessed the remainder as well as those excluded in this process. Initial 
research involved reviewing both title and abstract for eligibility and articles were be 
omitted if criteria were not met. The remaining were then further screened for eligibility 
and the reasons for exclusion of those that did not qualify were noted. At this point, the 
number of articles being utilized for data synthesis were identified (PRISMA, 2009).  
Data Collection and Synthesis 
Following the collection of articles, each one was meticulously reviewed and data 
were extrapolated. Data collected included types of non-adherence frequently seen in the 
research of patients prescribed oral chemotherapy and relevant statistics related to this 
information. Data was also collected on the various types of studies that were conducted 
in the research of each article. A chart was constructed and utilized to organize 
information extrapolated from articles which was adapted from an article by Fineout-
Overholt et al. (2010)- (Appendix B) . The data collection tool included title, year 
published, author(s), design method, sample, setting, major variables within a study, 
limitations, and findings related to barriers to adherence. Consistency in key terms was 
applied in order to accurately and succinctly represent the data. 
The PRISMA checklist (Appendix A) was utilized throughout to ensure 
completeness of findings and data summaries. The results section includes the 
characteristics of a given study, any potential bias noted, results of individual studies, 
how results were obtained, and any additional data collected. It was further used to 
discuss the summary of the evidence obtained, potential limitations, and conclusions 
(PRISMA, 2009). 
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In addition, charts were constructed to include the information from the PRISMA 
flowchart including- the number of articles, those obtained initially, those omitted, and 
the final number. This flowchart is a direct outline based on the PRISMA flowchart itself 
(Appendix C). Another was constructed to look at the main barriers types seen and will 
include common subsets within these headings.  
Critical Appraisal Tools: 
The critical appraisal of the data was made via the Critical Appraisal for 
Summaries Evidence, or CASE, worksheet (Appendix D).The authors (Foster & Shurtz, 
2013) aimed to develop a reliable tool to critically analyze evidence based point of care 
information? The authors identified five systematic reviews and greater than 100 primary 
articles following a literature review in CINHAL, EMBASE, MEDLINE, PsychINFO, 
and ERIC. Based in the information obtained from this search, the authors became aware 
of the importance of including in their worksheet information about of how evidence was 
both obtained and evaluated. It also had a moderate level of reliability among the rating 
of 384 summaries and was used to assess overall quality of evidence based practice. The 
CASE was developed using 10 questions that could be answered with either yes, no, or 
not completely (which applies to studies which possess incomplete data). Following each 
question, there are additional probing questions to assist researchers in answering the ten 
questions accurately. The questions within the worksheet include those pertaining to; 
topic, methods, content, and possible application to practice (Foster &Shurtz, 2013). 
The CASE worksheet was used to systematically assess the quality of research 
yielded from the final number of articles selected for the purpose of this study. It 
reviewed the “specificity, authorship, reviewers, methods, grading, clarity, citations, 
currency, bias, and relevancy” (Foster &Shurtz, 2013, p. 192) of the articles on an 
individual basis. The chart was also used to calculate the percentages of different barriers 
seen within the articles in order to identify those seen more frequently and their 
associated causes. Additionally, data was analyzed from the chart to examine the various 
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types of studies to increase the level of transparency and quality of research examined. 
Discrepancies found when comparing research studies was addressed in the synthesis of 
data as well (Appendix D). 
This study was performed without funding by a party that may increase bias of 
reporting on the part of the investigator. No conflicts of interest are included in the 
development of this project as well.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
The original search terms yielded 2046 studies, 1146 remained after removal of 
duplicates, and 1094 were eliminated following review of both title and abstract. Fifty-
two articles were retrieved in full text and reviewed by the author; another 35 were 
excluded as they did not fit inclusion and exclusion criteria. During data extraction two 
additional articles were excluded upon further review as they in fact did not meet criteria, 
yielding an N of 15 full text articles. The reasons for exclusion of the majority of articles 
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included: did not pertain to oral chemotherapy; non-nursing research; and examined 
nonadherence in regards to other conditions such as HIV/AIDS, diabetes, and post-
transplant patients. A flowchart illustrating selection of studies is depicted in Figure 1 on 
the next page. 
All studies were summarized in a data extrapolation chart (Appendix E). The 
findings were broken up into three main categories: patient related; system related; and 
nurse/provider related. Findings related to barriers to adherence from the articles were 
then placed in appropriate categories as illustrated in Table 1.  
Table 1.- Reasons for Patient Nonadherence to Oral Chemotherapy 
Reasons for Patient Nonadherence to Oral Chemotherapy 
Patient-Related • Adverse effects and toxicities (n= 9) 
• Forgetfulness (n=4) 
• Belief in efficacy (n= 2) 
• Depression (n=2) 
• Cancer type (n= 2) 
• Comorbidities (n= 1) 
System-Related • Regimen complexity (n= 6) 
• Financial (n= 4) 
• Pharmacy availability/locating specialty pharmacies (n= 3) 
• Time constraints of staff and poor staffing (n= 3) 
• Length of treatment (n= 1) 
Nurse/Provider-
Related • Patient education (n= 8) • Frequency and length of follow up visits (n= 5) 
• Nurses level of education/experience (n=2) 
• Physician experience (n=1) 
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Figure 1. Process for study collection utilizing the PRISMA Flowchart (N= 15) 
Patient-Related Factors 
 Within the heading of patient related, the most commonly cited barrier was 
adverse effects and toxicities as a result of oral chemotherapy were found in nine studies 
(Appendix F- # 1, 2, 3, 5, 6, 9, 13, 14, 15). Roop (2014; Appendix F #1) found that 
adverse effects were the second most prevalent cause of nonadherence (72%) in a 
descriptive study of 577 oncology nurses. Nurses within the study also reported that 
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patients frequently did not call with adverse effects as they felt they were bothering 
providers; others opted to “tough it out” or were more afraid of their cancers than they 
were of the side effects. Effects may increase to the point where patients decide to stop 
their oral chemotherapy medications altogether, but may not notify their physician 
(2014). 
 A qualitative meta-analysis with quantitative synthesis (Irwin & Johnson, 2015; 
Appendix F #2 ) found that as many as 69.8% of patients reported adverse effects as their 
cause for autonomously ceasing their treatment. The study of 159 full text articles also 
found that some patients will intentionally alter their dose or frequency in an attempt to 
combat those adverse effects. Adverse effects were shown to have a 40% frequency 
effect size from qualitative studies examined. Several studies within the meta-analysis 
found that improved management of symptoms increased rates of adherence (2015). 
 The three group pilot study of 119 patients conducted to assess the utilization of 
different interventions to increase adherence revealed that 80% (n= 95) of patients had 
the presence of at least one or more symptoms (Spoelstra et al., 2013; Appendix F #3). 
The patients were assessed by a registered nurse (RN) seven days following initiation of 
their oral chemotherapeutic agents and rated symptoms on average a four or more on a 
scale of 0-10. These patients were assigned to group two and were provided an RN to 
continue to follow up and assist with the management of their symptoms. Group one 
subjects were referred to materials to assist with self-management of symptoms and 
group three were called by an RN to assess adherence. Group two was found to have the 
most significant decrease in symptom severity, down 6.76 as compared with group 1 
(4.74) and group 3 (2.16). The study also found that within group 2, although originally 
with the highest rate of nonadherence, rates decreased with each week of the study, 
suggesting that improved symptoms increased rates of adherence. This finding is 
consistent with a study conducted via a focus group of patients either past or present on 
oral chemotherapy (Simchowitz et al., 2010; Appendix F #5). Patients expressed that they 
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did not feel comfortable managing their adverse effects and they often affected adherence 
rates.  
 In a descriptive feasibility pilot study (Sommers et al., 2012; Appendix F #6) of 
30 patients with gastrointestinal cancer at an outpatient oncology center, it was 
discovered that 17 (57%) patients reported adverse effects within 72 hours of initiating 
oral chemotherapy. Eight out of the 17 (57%) patients required further assistance 
managing their effects while on oral chemotherapy. Seven patients had therapy stopped 
due to toxicities from their treatment and it was found that most patients could not 
articulate drug specific side effects to report to their providers. The importance of 
managing adverse effects of oral chemotherapy can be easily demonstrated as was seen in 
one systematic review of 131 articles (Sansoucie and Spoelstra, 2015; Appendix F #9). 
This review found that most interventions to increase adherence were targeted to 
managing symptoms. Interventions geared towards the management of adverse effects 
were listed as recommended for practice to increase adherence.  
 Another systematic review found that the most common treatment-related reason 
for nonadherence to oral chemotherapeutic agents included adverse effects to treatment 
of various cancers (n=5) (Verbrugghe et al., 2013; Appendix F #14). The studies 
analyzed focused on breast, chronic myeloid leukemia (CML), and colon cancer; the 
most common being breast. One study found that as many as 70% of patients within that 
study reported nonadherence related to symptom severity. The authors recommended 
early intervention and education about side effects to patients on oral agents (2013). This 
is consistent with another study qualitative study where of the 10 patients who were 
intentionally nonadherence, the most common reason noted was due to adverse effects or 
in an attempt to minimize side effects experienced by the patient (Eliasson et al., 2011; 
Appendix F #15). This study was conducted on patients taking imatinib for the treatment 
of CML.  
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 One descriptive exploratory study of 30 oncology patients with comorbidities 
found that patients averaged 5.1-5.6 on a symptom severity scale of 1-10 (Given et al.; 
2015; Appendix F #13). Those patients with the higher number of comorbid conditions 
reported higher levels of adverse effects and often felt that the management of their 
cancer and side effects interfered with the management of their other conditions which 
led to decreased adherence rates at times. There was also a relationship found between 
younger age and increased symptoms severity which may be attributed to more 
aggressive treatment in younger populations leading to potentially decreased adherence 
rates (2015). 
 The second most common patient-related factor noted in the research pertained to 
patient forgetfulness when taking their prescribed oral chemotherapeutic agent (Appendix 
F- # 2, 10, 14, 14). Irwin and Johnson found that forgetfulness was the most commonly 
reported reason for unintentional nonadherence in patients (2015: Appendix F #2). Their 
meta-analysis found a 38% frequency effect size from qualitative studies and 27 articles 
listed forgetfulness as a common cause of nonadherence out of the 159 within the study.  
 Mathes et al. (2014; Appendix F #10) found in their systematic review that 
forgetfulness was cited by numerous authors and their studies were directed at 
interventions to address this aspect of nonadherence. Of the six studies included in the 
review, one showed the intervention to have statistical relevance in increasing adherence, 
three studies were in favor of interventions, and two had mixed results. The interventions 
utilized and studied were primarily medication reminders for patients or Medication 
Event Reporting Systems which records when a patient opens their medication bottle to 
assess for missed doses as well as patient education. Another systematic review by 
Verbrugghe et al., (2013; Appendix F #14) found that forgetting was the most common 
cause of unintentional nonadherence (n=2).  
System-Related Factors 
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 Within the heading of system related factors, one of the most commonly seen 
factors was regimen complexity (Appendix F- # 1, 2, 3, 4, 7). Roop and Wu (2014; 
Appendix F #1) found in their national online survey that the largest perceived barrier 
from nurses to patient adherence was in relation to complex regimens (n= 237: 41%). 
These nurses felt that complicated directions for medication administration was the 
number one reason for nonadherence among their patients. Several reported that they 
have had some success with the implementation of follow up phone calls as well as 
medication calendars. 
 Complexity of a patients’ oral chemotherapy regimen was also cited by Irwin and 
Johnson (2015; Appendix F #2) as a cause of nonadherence in their meta-summary 
analysis. Although the evidence was not as strong as was seen with some other factors 
analyzed, there was a 22% (n=14) frequency effect size from the qualitative studies 
examined. The authors suggested, however, that lack of research pertaining to this topic 
was in part why there was not more evidence to support it as a more significant cause of 
nonadherence. This is supported by a pilot study (Spoelstra et al., 2013; Appendix F #3) 
which found that with increased complexity, there was also an increased in missed doses 
of medication. Patients within the study who were on continuous regimens had an 
adherence rate of 88% versus those on a 14 days on and seven days off regimen which 
had only a 35% adherence rate. Additionally, for those on a seven days on and seven days 
off regimens, only 33% were adherent and all other types of complex regimens were 
found to have on average only a 50% adherence rate.  
 The secondary analysis of the previous study mentioned looked at the effect of 
regimen complexity on over-adherence (Spoelstra et al., 2013; Appendix F #4). Over-
adherence is defined by WHO as occurring when a patient takes greater than the 
prescribed amount of medication, either in dose or frequency (2003). The research found 
that of the patients with a simple continuous regimen, only one was overly adherent as 
compared with those patients on regimens with 14 days on and seven days off which had 
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12 patients who reported over-adherence. Patients with regimens with seven days on and 
seven days off had six report over-adherence during their cycle. Over-adherence also 
places the patient at risk for adverse effects and toxicities which can also affect adherence 
rates as previously described.  
 In addition to regimen complexity, financial barriers were common reasons for 
nonadherence (Appendix F- # 1, 2, 5, 14). One study surveying oncology nurses found 
that 81% (n=467) felt that cost of oral chemotherapy was the largest cause of 
nonadherence (Roop & Wu, 2014; Appendix F #1). Many felt that high cost of drugs also 
made it more difficult to obtain authorization through insurance companies causing 
delays in administration. Additionally, when there were high out-of-pocket costs for 
patients and financial assistance was required, applications were long and tedious which 
further delayed treatment. Nurses expressed concerns that at times chemotherapy 
teaching occurred long before patients were able to physically obtain the medication due 
to cost which may have affected information retained by patients provided in the teaching 
sessions (2014).  
 Irwin & Johnson (2015; Appendix F #2) in their meta-analysis found that cost of 
medication was a common cause of unintentional nonadherence for patients. The study 
found that there was a 26% size effect with cost of oral chemotherapy affecting 
adherence and was supported by 19 studies out of the 159 analyzed. Simchowitz et al. 
(2010; Appendix F #5) also found that cost and insurance were frequently a common 
reason for a patient’s inability to take medication as prescribed. Patients within the focus 
group articulated that there were frequent issues negotiating costs with insurance 
companies in order to be able to afford their medication. Others reported that they often 
required assistance from the pharmacist, nurse navigator, family, and even a United 
States Senator for assistance in obtaining coverage for their oral chemotherapy (2010). 
Financial hardships for patients in relation to out-of-pockets costs for medication is 
further supported by Verbrugghe et al. (2013; Appendix F #14,). The authors found that 
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even a copay as low as $30 may prohibit many patients from being able to afford their 
medication. Higher out of pocket costs were associated with poor adherence in patients 
being prescribed oral chemotherapy in the study.  
Nurse/Provider-Related Factors 
 There are also several nurse and provider related factors that have the potential to 
affect patient adherence on oral chemotherapy. The most commonly seen within was in 
relation to patient education (Appendix F- # 5, 6, 7, 8, 9, 10, 11, 14). One study which 
performed a focus group with both current and former patients prescribed oral 
chemotherapy expressed a desire for increased education related to their medication 
(Simchowitz et al., 2010; Appendix F #5). Many patients within the study felt they were 
ill-prepared to be aware of side effects to expect, how to manage them, and when to 
report side effects to their providers. They also expressed a desire to have been informed 
more thoroughly what symptoms were considered normal based on their particular 
medication versus what was a “red flag” to be reported immediately to providers. Many 
also felt that they retained very little from their original education session and felt that it 
would be beneficial to have frequent reinforcement and additional information provided 
to them (2010).  
 Sommers et al. (2012; Appendix F #6) found in their study of 30 patients that 21 
(70%) could not identify the most common adverse effect related to their medication. 
None of the patients in the study on temozolomide (n=5) could verbalize understanding 
or identify that hematologic toxicities were associated with the medication. Another 50% 
of patients within the study (n=3) on sorafenib were unable to identify hypertension as an 
adverse effect associated with their medication or to monitor their blood pressure. The 
investigators found that follow-up phone calls from the nurse to reinforce information 
discussed at teaching visits was helpful in minimizing non-adherence related to 
knowledge deficits (2012).  
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 The authors of an Australian study who conducted an education program for 
patients on oral chemotherapy found some staggering results in relation to patient 
education (Griffiths & Pascoe, 2014; Appendix F #7). Prior to patient education being 
provided, only 46.7% (n= 7) of the 15 patients in the study could correctly identify the 
name of their medication as compared to 100% following education. Only 66.7% (n=10) 
knew when to take their medication and only 60% (n=9) knew how many tablets to take 
at a time versus following education where rates increased to 100% for both questions. 
Investigators in the study also found that only a mere 20% (n=3) knew the main adverse 
effects associated with their specific oral chemotherapy medication, this rate also 
increased to 100% following the education program. In relation to medication safety, 
none of the patients within the study could accurately articulate to researchers where a 
safe place would be for them to store their medications (2014). 
 Another study conducted in Japan surveyed nurses on their perceptions of their 
practice related to patients on oral chemotherapy (Komatsu et al., 2014; Appendix F #8). 
Nurses reported that only 58.1% (n= 36) assessed their patients understanding of their 
medication as well as 75.8% (n= 47) provide education to their patients on how to 
manage their adverse effects. Of the nurses who participated in the survey 64.5% (n= 40) 
responded that they confirmed patient understanding of their medication regimen, 
however 93.5% (n= 58) stated that if their patients articulated that they did not 
understand they provided them with additional information.  
 Patient education as the sole intervention on adherence was found to have little 
evidence to support use, but was found to be recommended for practice when combined 
with other modalities such as reminders and close follow up (Sansoucie & Spoelstra, 
2015; Appendix F #9). Some studies analyzed in the systematic review did show a 
positive effect on patient adherence while others were inconclusive or with mixed results. 
Researchers found, however, that when used in conjunction with other techniques, 
education was very effective in assisting patients. Ten random control trials (RCTs) 
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found that when used in combination with other interventions, there was a significant 
increase in adherence rates. Research conducted on education as a sole intervention was 
found to have mixed results with five studies showing a positive effect on adherence 
while another four found no effect.  Another systematic review conducted in Germany 
found that of the six articles in their study, two utilized patient education as part of their 
interventions to increase adherence and found positive results (Mathes et al., 2014; 
Appendix F #10). Of note in this study, data was not reported on statistical results of 
adherence and no control group was utilized in either study. 
 One study utilizing in-service programs, which were conducted in various 
healthcare settings across the northeastern United States, found that nurses often did the 
not have the tools or knowledge to provide personalized education to patients to increase 
adherence (Matthews & Holland Caprera, 2014; Appendix F #11). Based on the survey 
of nurses present at the in-services, the researchers articulated the need for increased 
education for patients and caregivers regarding their oral chemotherapy in order to 
prevent nonadherence as well as to prevent adverse effects which also may lead to 
nonadherence. They further stated the need for follow up after initiation of therapy to 
provide reinforcement of education and possible interventions as needed. No specific data 
regarding the survey administered to nurses was provided nor was understanding of 
providers knowledge of the oral chemotherapies (2014). 
 The systematic review conducted by Verbrugghe et al. (2013; Appendix F #14) 
found that of the 25 studies included, several (n= 4) found that lack of or poor patient 
education contributed to lack of consistent patient adherence with oral chemotherapy, 
while an others (n=3) found a positive effect on adherence with increased knowledge and 
education prior to initiation of treatment. One study found a lack of education regarding 
the consequences of nonadherence, another found similar results in regards to poor 
patient education on potential adverse effects and what to report. One study found a lack 
of education to patients prior to initiation of chemotherapy during the review of treatment 
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options available and stated that more information would have assisted patients with 
making different choices regarding their chemotherapy. Another study found a general 
lack of knowledge and education from providers in regards to their disease, prognosis, 
and treatment options. Findings an overall need for increased patient education in all 
areas of care along the continuum (2013). 
 The second most commonly seen theme within the nurse and provider-related 
heading was related to follow-up with patients on oral chemotherapy affecting adherence 
rates (Appendix F- # 3, 5, 6, 11, 14). Spoelstra et al. (2013; Appendix F #3) found that 
within their three control groups, the one that provided patients with the Automated 
Voice Recording (AVR), nurse follow up calls, and interventions as needed for 
symptoms had the lowest rates of nonadherence (33%). This compares with the first 
group which only received the AVR (40%), and the third group which received the AVR 
as well as the nurse follow-up calls, but without interventions (53%). All Results from all 
groups supported that with increased number of contacts with the patients, the rates of 
adherence increased over time (2013).  
 Another study conducted via a patient and caregiver focus group found that 
although all patients within the group reported follow-up with their providers, there was a 
wide variety between what type of follow-up and how often (Simchowitz et al., 2010; 
Appendix F #5). Many patients within the study expressed a need for follow-up with 
providers in-between appointments, specifically in regard to the management of their 
symptoms. They felt that all of the responsibility fell upon them as the patient to call and 
report symptoms. Several patients also felt that they were often unsure what to report and 
what symptoms were considered expected and did not always feel comfortable calling 
their providers. Some patients who had previously been part of a clinical trial felt that 
they were left on their own and were upset by lack of follow-up as compared with being 
part of a clinical trial where follow up was performed frequently and symptoms were 
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monitored closely. There was an overall agreement that follow-up of those on oral 
chemotherapy should reflect that of patients on clinical trials (2010). 
 Sommers et al. (2012; Appendix F #6) performed a study that included a follow-
up call to patients from an RN 72 hours after initiation of oral chemotherapy treatment. 
They found that at that time, most patients had begun to experience side effects from their 
medications and reported increased satisfaction with the increased follow-up. Nurses 
were able to assess side effects, answer questions, assess needs of the patient and their 
caregivers, and refer to a provider as needed. They also found that patients were not able 
to articulate to nurses what side effects to reports, what were specific to their particular 
medication, or how to manage their side effects. The call from the RN allowed for 
interventions as needed, increased education, and triggered follow up with providers if 
needed as well (2012).  
 Many nurses and physicians reported frustration in regard to time constraints 
prohibiting or limiting their ability to provide increased follow up with patients on oral 
chemotherapy (Matthews & Holland Caprera, 2014; Appendix F #11). Providers included 
in the survey communicated that they often spent large amounts of time obtaining 
authorization for medications, finding pharmacies that carry the medication, and 
obtaining financial assistance as needed, which decreased time spent with patients and 
with appropriate follow up. Several nurses in the study felt that decreased time spent 
talking with patients had the ability to decrease adherence for several reasons including 
knowledge deficits and adverse effects. They also articulated a lack of individualized 
follow up plans for each patient based on their specific needs such as in regards to 
transportation or work schedules which may require a follow up telephone call versus 
being seen in person.  
 One systematic review also found a correlation between follow-up and effect on 
adherence with patients being prescribed oral chemotherapy (Verbrugghe et al., 2013; 
Appendix F #14,). One study reported that short duration of follow-up appointments had 
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a negative effect on adherence. This negative effect was also seen with three other 
studies, which found that follow up with providers other than their attending oncologist 
had the potential to decrease patient adherence rates. Conversely, longer duration of 
follow in addition to an increase in the number of follow up appointments with providers 
were seen in two studies as having the ability to increase patient adherence in CML 
patients.  
 Other data extrapolated was presented in further details in appendix F.   
 Next, summary and conclusions will be presented.  
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Summary and Conclusions 
Currently 25% of new cancer drugs in development are via the oral route and this is 
expected to continue to grow (Verbrugghe et al., 2013). Research collected in this 
systematic review showed that healthcare providers are struggling with chemotherapy 
administered orally due to its’ relative newness. Currently few institutions have adequate 
policies and procedures in place to monitor patients on these medications (Roop & Wu, 
2014). Patients have reported a lack of follow-up, verbal and written education, 
information regarding adverse effects and availability of providers to answer questions 
regarding their oral chemotherapy treatment (Quality Health, 2014).  
 With an estimated death rate of 125,000 patients annually due to nonadherence to 
oral chemotherapy as well as a 10-23% increase in skilled nursing facilities and hospital 
admissions, there is clearly a need for increased focus on this issue (Moore, 2010). With 
reports that as high as 40% of patients are lacking knowledge related to how to correctly 
self-administer their oral chemotherapy medications (Griffiths & Pascoe, 2014), it is 
obvious that additional emphasis, resources and education are needed. This is further 
supported by documented lack of financial resources for many individuals given that 
costs of oral chemotherapy medications can range from $12,644.28-$30,690.31 monthly 
(Bwayo-Weaver et al., 2013).   
There is a steep learning curve for healthcare providers who provide care for 
patients on oral chemotherapy. There are also crucial differences in the care provided as 
compared to those who receive intravenous chemotherapy. Patients on intravenous agents 
often experience more frequent assessments and interventions since the medication is 
administered in a clinic or infusion center by nurses who assess them. Additionally, many 
intravenous regimens necessitate that patients be seen for infusions as often as daily, for 
several consecutive days, which facilitates close assessment.  
The purpose of this systematic review was to identify causes of nonadherence to 
oral chemotherapy on the part of the patient and their caregivers. Studies were selected 
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through a comprehensive literature review using selected key terms. The initial search 
yielded 2046 studies; next duplicates were removed and inclusion and exclusion criteria 
were applied. A final total of 15 studies met all of the pre-set criteria. The most prevalent 
barriers to adherence that were identified were categorized into three common themes: 
patient-related factors; system-related factors; and nurse and provider-related factors 
which were then broken down further, with findings appropriate to the respective themes 
identified. Certain themes were seen with increased frequency in the, including adverse 
effects, patient forgetfulness, regimen complexity, financial barriers, patient education, 
and necessary follow up. This suggests that these factors should be carefully assessed by 
providers caring for these patients.  
There were certain limitations that existed in conducting this systematic review. 
During data collection and initial analysis of the available research, it was evident that 
there were only a small number of studies pertaining to patients taking oral chemotherapy 
specifically: this affected sample size which was relatively small. Several studies relied 
heavily on patient self-report which is subject to the Hawthorne effect and may be 
inaccurate. Two systematic reviews (Irwin & Johnson, 2015; Mathes et al., 2014) 
included studies of poor methodological quality which may have affected the results 
conveyed. Also, adherence rates were difficult to assess and compare given the fact that 
criteria for adherence varied greatly from one study to the next and without a consistent 
definition. For instance Verbrugghe et. al (2013) found that researchers considered a 
patient non-adherent if they took their medication anywhere from <80% to <100% of the 
time and were over-adherent if they took >110% of their prescribed medication . Another 
study defined a patient as under-adherent if they missed greater than 20% of their 
medication within a seven day period (Spoelstra et al., 2013). Yet another study defined 
optimal adherence as occurring when a patient takes all doses of a medication, every day 
at the right time, without missed or extra doses (Komatsu et al., 2014).  
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 In conclusion, nonadherence in patients who are prescribed oral chemotherapy 
will continue to be a problem as the number of oral oncolytics continues to increase. The 
researcher was able to shed light upon the fact that nonadherence is related to multiple 
and diverse factors and thus one intervention alone will not be successful in 
circumvention. Care of patients taking oral chemotherapy needs to be highly 
individualized and the nurse has an important role in the monitoring of this vulnerable 
population. Nonadherence is multi-factorial with many variables for healthcare 
professionals to consider. Numerous opportunities exist to improve care of people 
prescribed oral chemotherapeutic agents and these will be discussed in the next section.   
 
 
 
 
 
 
 
 
Recommendations and Implications for Advanced Nursing Practice 
The information collected and analyzed in this study has provided evidence for 
recommendations for practice changes among advanced practice nurses (APNs). There 
was a lack of nursing education and knowledge pertaining to the issues surrounding 
potential barriers to adherence among new and existing nurses in the research. With the 
large increase of the number of available oral therapies available and being ordered for 
patients, nurses need to be abreast of the adverse effects and implications for both the 
patients and their caregivers to help them circumvent potential issues. This also extends 
to novice nurses coming into the field as well.  
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Schools of nursing need to provide education to both undergraduate and graduate 
students in regard to adherence of patients on oral medications so that they are aware of 
this challenge in their practice. Likewise, the potential causes of nonadherence, the risks 
associated with nonadherence, and strategies to assist with decreasing its’ incidence need 
to be addressed. Future APNs should understand that they will need to provide education 
within their respective roles to both patient and healthcare staff alike on the topic. 
Hospitals and other healthcare institutions can include the topic within their new staff 
orientation and maintain the knowledge through annual competencies. As rates of 
readmission increase, which costs institutions as well as providers reimbursement, it 
certainly behooves them to maintain a focus on this issue at consistent intervals. The 
APN has a vital role in also discussing these issues of noncompliance with other team 
members and physician colleagues.  
 Increased communication among all healthcare providers caring for patients 
taking oral chemotherapeutic agents is key to improving outcomes. Studies identified that 
patients want increased information as well as options in their care including adverse 
effects to expect and report. Increased follow up with consistent providers increased 
patient adherence to their regimens which is an important factor as well. Attempts to 
maintain and increase consistency of providers represents an important leadership role of 
the APN. Nurses articulated in several studies the need for increased communication 
between interdisciplinary providers of patients on oral chemotherapy to increase their 
assessment of the patients. As with all aspects of nursing and in healthcare in general, 
communication from provider to provider in addition to from provider to patient is highly 
crucial to provide the best possible care to patients. 
 Several studies which collected data from nurses also found a deficit in the 
availability or accessibility of policies to guide nursing practice related to patients on oral 
chemotherapy regimens. It is recommended that all patient care areas which administer 
these potent medications have policies and procedures in place and accessible to all staff 
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to refer to in order to increase patient safety. These policies should include, but not 
necessarily be limited to, how to manage patients, follow up needed and how often, how 
to track patients on these medications in the medical records, as well as how nurses 
should be notified that a patient is being placed on the medication by the providers. 
Policy development most certainly falls under the umbrella of roles for the APN as it 
pertains to increasing patient outcomes and overlaps with evidence based practice (EBP). 
The APN is in a position to provide expertise in the development of policies and 
protocols given their education and knowledge of EBP which is a necessity in their 
development. All policies and protocols created need to be backed by evidence to support 
their statements and positions. Additionally, the APN is important for the implementation 
and education of staff about their existence, as well as how to use them and when.  
 Nursing leadership also plays an important role in bettering the outcomes of this 
patient population as well. There are often difficulties obtaining insurance coverage or 
affordable co-pays for patient’s on these medications. Many insurance companies do not 
cover oral chemotherapies, require prior authorizations, additional research to be 
submitted to prove potential efficacy, or have incredibly high out of pocket costs. The 
APN is in prime position to act on legislation to ensure coverage for these life saving 
medications for all patients who should not have to choose between a less effective 
treatment and one that they cannot afford. This can be accomplished by collaboration 
with other politically active APNs to change laws which would mandate the coverage of 
these life saving medications, expedite their appeals to delay care, and allow for 
reasonable co-pays for patients. Legislation in this area has the potential to save lives, 
decrease nonadherence which can lead to disease progression, and increase access to 
care.  
Advanced practice nurses have the ability to obtain and allocate funds for patients 
to assist with out-of-pocket costs when available through fundraising and increased 
awareness of the financial obstacles that many patients face. Networking with other 
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healthcare professionals, APNs have the capability to articulate the issues surrounding 
this barrier to adherence in patients on oral chemotherapy and potentially increase the 
amount of patient assistance funds available. Providing this information to staff who 
provide direct care and may be assisting with obtaining financial assistance or dealing 
with insurance companies is equally important. Nurses should be aware of changes to 
insurance coverage, specifically those covered by both state and federal which many 
patients have.  
 With more and more institutions and practices utilizing the electronic medical 
records (EMR), several aspects of use will fall upon the shoulders of the APN. From 
development to initiation to staff education, the APN’s role is very versatile and 
important. Within the EMR, APNs can collect quality and safety data as well as assess 
patient safety measures which can be utilize to assist in benchmarking against other 
institutions. They can also perform audits to ensure adequate assessment and 
documentation from all providers in addition to ensuring proper follow up for patients on 
oral chemotherapy regimens. Additionally, APNs can be instrumental in the development 
of order sets within the EMR which can make information more readily available to other 
healthcare providers and in a more standardized way.  
 Several gaps in the research remain in regards to the many issues surrounding 
nonadherence with patients on oral chemotherapy. Many of the studies found in the 
literature search pertained to other patient populations or included these populations in 
with oncology patients such as patients with COPD, HIV, and transplant patients. There 
is a lack of research from nurses regarding the many issues surrounding adherence in 
patients on oral chemotherapy. A need exists for the APN to increase the body of 
knowledge that is available to other healthcare professionals by participating in research 
in this area. With increased research available, recommendations for evidenced based 
practice will allow nurses and providers to target their care more directly to patient needs. 
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 While there was not statistical evidence of various demographics affecting rates 
of nonadherence, there were some studies that suggest that race, ethnicity, language, and 
age all play a role in adherence. The APN working with both patients and practitioners 
have the ability to assist with screening potential patients for appropriateness as well as 
providing education to staff nurses who directly care for them. They also have the ability 
to ensure informed consent is being obtained to maintain ethical practice and patients are 
being offered choices in their care. Utilizing the APN to the greatest extent of their 
certification and licensure will increase patient satisfaction, decrease admission rates and 
length of stay, and decrease healthcare dollars spent. They are in a position to accomplish 
this all while providing excellent and cost efficient care to the hematology/oncology 
patient who often has many needs in all aspects of care. The key to managing this 
complex and very ill patient population is communication between all specialties and 
providers as well as interdisciplinary care to optimize patient outcomes to the greatest 
extent possible.  
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Critical	Appraisal	for	Summaries	of	Evidence	(CASE)	Worksheet	
*Numbers	in	evaluation	correspond	with	those	assigned	to	articles	in	data	extrapolation	chart*	
Questions	 Evaluation	
Summary	Topic	
1. Is	the	summary	specific	in	scope	and	
application?	
Yes-		
Not	completely-	
No-	
Summary	Methods	
2. Is	the	authorship	of	the	summary	
transparent?	
Yes-		
Not	completely-	
No-	
3. Are	the	reviewer(s)/editor(s)	of	the	
summary	transparent?	
Yes-		
Not	completely-		
No-		
4. Are	the	research	methods	transparent	
and	comprehensive?	
Yes-		
Not	completely-		
No-	
5. Is	the	evidence	grading	system	
transparent	and	translatable?		
Yes-		
Not	completely-		
No-	
Summary	Content	
6. Are	the	recommendations	clear?	 Yes-		
Not	completely-	
No-		
7. Are	the	recommendations	
appropriately	cited?	
Yes-	
Not	completely-		
No-		
8. Are	the	recommendations	current?	 Yes-		
Not	completely-	
No-	
9. Is	the	summary	unbiased?	 Yes-		
Not	completely-	
No-	
Summary	Application		
10. Can	this	summary	be	applied	to	your	
patient(s)?	
Yes-		
Not	completely-	
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Appendix F 
	 Citation	of	
article	
Design	Method	 Sample	 Setting	 Major	
variables	
within	study	
Limitations	 Findings	related	to																																	
nonadherence	
1	 Current	
practice	
patterns	for	
oral	
chemotherap
y:	results	of	a	
national	
survey.	Roop	
JC;	Wu	HS.		
Oncology	
Nursing	
Forum.	41(2):	
185-94,	2014	
March	1.																																					
*Descriptive	study-	
three	phase	study.	
*Phase	1-
development	of	the	
survey	tool	
*Phase	2-	validation	
of	the	survey	tool	
*Phase	3-	
implementation	and	
distribution	of	the	
survey	tool.		
*The	final	survey	
consisted	of	26	
items-	1 addressing	
consent,	7	looking	
at	demographic	
information,	17	
addressing	content	
areas	using	a	Likert-
type	scale,	and	1	
free	text	question	
for	participants	to	
respond	to.	
577	oncology	RNs	
*96%	female	
*91%	Caucasian	
*75%	worked	full	
time	
*85%	worked	in	the	
outpatient	setting	
*52%	had	worked	
greater	than	15	
years	in	oncology	
*42%	held	a	
bachelor’s	degree	in	
nursing	
*5,000	total	
surveys	were	
delivered	
electronically	to	a	
national	sample	of	
nurses	within	the	
Oncology	Nursing	
Society	
*After	the	initial	
email,	recipients	
received	a	
reminder	email	2	
weeks	following	
*The	survey	was	
open	for	a	total	of	
10	weeks	from	
April-	June	2012	
*Practices	
pertaining	to	
patient	care																
*Nursing	
resources													
*	Barriers	to	
medication	
adherence	
*First	use	of	survey	
utilized,	limited	
validity																							
*Low	response	rate-	
13%	
	*No	personal	
information	from	
RNs	collected	
*Lack	of	diversity	
among	respondents		
*81%	RN	reported	financial	
burden	greatest	cause	of	
nonadherence																						
*Second	greatest	burden	
identified-	Adverse	effects	
(72%)		
*Third	greatest	identified-	
regimen	complexity	(41%)	
*Only	53%	of	nurses	
reported	having	policies	
and	procedures	in	place	to	
help	manage	patients	on	
oral	chemotherapy	
*56%	agreed	that	there	
were	systems	in	place	to	
inform	them	when	a	patient	
was	placed	on	oral	
chemotherapy	to	assist	with	
follow	up	and	management.		
*Noted	in	free	text	
comments	that	there	is	
little	support	for	patients	on	
oral	chemotherapy	
compared	with	IV-	“oral	
patients	are	slipping	
through	the	cracks”	
*RNs	reported	issues	
surrounding	poor	
healthcare	provider	
communication	
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*Concerns	for	lack	of	time	
for	education-	management	
became	reactive	instead	of	
proactive	as	a	result.	
2	 Factors	
influencing	
oral	
adherence:	
qualitative	
metasummar
y	and	
triangulation	
with	
quantitative	
evidence.	
Johnson	LA.	
Clinical	
Journal	of	
Oncology	
Nursing.	19(3	
Suppl):	6-30,	
2015	Jun.																				
Qualitative	meta-
analysis	with	
quantitative	
synthesis	
*3	literature	
searches	of	PubMed	
and	CINAHL	of	
qualitative	studies	
analyzing	adherence	
to	oral	medications.	
*Studies	were	
excluded	if	they	
included	samples	of	
patients	with	
psychiatric	illness,	
substance	abuse,	or	
taken	by	route	
other	than	oral.		
*Key	terms	
included-	
compliance,	
medication	
adherence,	oral	
medication,	oral	
chemotherapy,	
antineoplastic	
Initial	search	yielded	
26,936	articles.	
*576	remained	after	
removal	of	
duplicates	and	
initial	review	
*187	remained	
following	secondary	
review	
*Final	review	of	
inclusion	and	
exclusion	criteria	
yielded	a	final	n	of	
159	full	text	articles	
N/A	 *Key	terms	
used	in	
literature	
search																					
*Inclusion/excl
usion	criteria	
*Looked	only	
at	qualitative	
studies	
*Included	studies	
with	noncancer	
diagnoses							
*Limited	evidence	
in	patients	with	
cancer	as	compared	
with	other	diseases							
*Nature	of	some	of	
the	qualitative	work	
studied	
*Factors	associated	with	
either	increased	or	
decreased	adherence	were	
the	same	for	both	patients	
with	cancer	and	those	with	
other	diseases	
*Factors	associated	with	
decreased	adherence	with	
all	patients:	adverse	effects,	
forgetfulness,	financial	
burden	or	lack	of	insurance,	
lifestyle,	increased	pill	
burden,	and	regimen	
complexity	
*Cancer	patient	specific	
causes	of	nonadherence-	
depression	and	negative	
expectations	of	medication	
efficacy																																																						
*No	relationship	between	
age,	gender,	and	adherence	
seen		
*Multiple	factors	that	
contribute	nonadherence-	
suggests	a	multifactorial	
behavioral	issues	
surrounding	nonadherence		
*Recommended	increased	
research	on	patients	
specific	to	cancer.	
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3	 An	
intervention	
to	improve	
adherence	
and	
management	
of	symptoms	
for	patients	
prescribed	
oral	
chemotherap
y	agents:	and	
exploratory	
study.	
Spoelstra	SL;	
Given	BA;	
Given	CW;	
Grant	M;	
Sikorskii	A;	
You	M;	
Decker	V.	
Cancer	
Nursing.	
36(1):	18-28,	
2013	Feb.	
3	group	pilot	study-	
goal	was	to	assess	
efficacy	of	an	
Automated	Voice	
*Response	(AVR)	
system	affected	
adherence	to	oral	
chemotherapy.	
*Group	1	of	
participants	(n=	40)	
received	only	the	
AVR	
*Group	2	(n=	
40)received	the	AVR	
in	addition	to	
obtaining	strategies	
to	increase	
adherence	
*Group	3	(n=39)	
received	AVR,	
strategies	to	
increase	adherence,	
and	manage	their	
symptom	
*Study	took	place	
over	a	10	week	time	
span	and	all	119	
participants	
received	a	baseline	
interview,	a	
symptom	
management	
toolkit,	and	an	exit	
interview.		
*Data	analyzed	by	
*119	Patients	with	
solid	tumors,	
greater	than	the	age	
of	21,	not	on	
hormonal	oral	
agents,	could	
understand	and	
speak	English,	were	
without	hearing	
defects,	without	
cognitive	delays	or	
emotional	and	
psychological	
disorders,	and	
owned	a	touchtone	
phone.		
*Average	age-	59.6	
*69%	female	*33%	
breast	cancer	
patients	
*54%	on	complex	
regimens		
National	Cancer	
institute-	both	
community	cancer	
center	and	
comprehensive	
cancer	center,	
private	oncology	
group,	and	another	
comprehensive	
cancer	center	
*Symptom	
Management	
Toolkit																																								
*Group	1-	
received	calls	
from	an	
automated	
voice	
response(AVR)
,	Group	2-	
received	calls	
from	an	APRN	
to	manage	
symptoms/ad
herence	+	
AVR,	Group	3-	
APRN	+	
adherence	+	
AVR	
*Patient	
characteristics	not	
consistent-	e.g.-	>	
number	of	
Caucasian	versus	
other	ethnicities																													
and	>	number	of	
females	versus	
males					
	*Only	includes	
patients	with	solid	
tumors	
*Participants	were	
asked	to	participate	
by	nurse	recruiters	
which	limits	random	
sampling.		
*Adherence	rates	similar	
among	all	3	groups	with	an	
overall	adherence	level	of	
42%																																														
*Decrease	in	symptom	
severity	in	group	2	which	
assisted	with	adverse	
effects	management	found	
slightly	higher	levels	of	
adherence-	suggests	
decreased	symptoms	may	
increase	adherence																				
*Sites	adverse	effects	and	
complex	regimen	as	being	
related	to	either	
overadherence	or	
underadherence.	
*	Found	increased	number	
of	contacts	with	patients	
increased	adherence	rates	
*Found	that	cancer	site,	
drug	being	prescribed	
(which	depends	on	the	type	
of	cancer),	and	medication	
regimen	were	associated	
with	adherence	levels.		
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an	intent	to	treat	
analysis	
4	 Issues	related	
to	
overadherenc
e	to	oral	
chemotherap
y	or	targeted	
agents.	
Spoelstra	SL;	
Given	BA;	
Grant	M;	
Sikorskii	A;	
You	M;	
Decker	V.	
Clinical	
Journal	of	
Oncology	
Nursing.	
17(7):604-9,	
2013	Dec.	
Longitudinal	
secondary	analysis	
of	study	#3	as	
described	above.	In	
addition	to	above	
methods,	this	
secondary	analysis	
looked	more	in	
depth	at	socio-
demographic	
information,	looked	
at	medical	records	
for	evidence	of	
dosing	changes	to	
oral	chemotherapy,	
pulled	pharmacy	fill	
information	and	
compared	with	
records.	
*Researchers	
assessed	
overadherence	in	
more	detail	than	the	
original	study	by	
also	analyzing	
adherence	rates	
against	regimen	
complexity.	
100	Patients	with	
solid	tumors	of	the	
119	within	the	
sample	as	
previously	described	
in	article	#3	
Outpatient	
oncology	clinics	at	
4	sites	as	described	
above	in	article	#3	
*Regimen	
complexity-	
categorized	
into	4	groups-	
1)	continuous	
(same	
medication	is	
taken	every	
day),	2)	
regimens	
where	
patients	took	
medication	on	
days	1-14	
followed	by	no	
medications	
days	15-28,	3)	
patients	who	
were	
prescribed	
medication	to	
be	taken	7	
days	
consecutively	
followed	by	7	
days	off,	and	
4)	all	other	
dosing	
regimens	
*Patient	
characteristics	not	
consistent-	e.g.-	>	
number	of	
Caucasian	versus	
other	ethnicities																													
and	>	number	of	
females	versus	
males					*Only	
includes	patients	
with	solid	tumors	
*Did	not	include	all	
119	of	the	original	
sample	size	
*	33/100	found	to	be	
nonadherent	with	
treatment-	20/33	being	
overadherent	and	13/33	
under-adherent	
*Relationship	was	found	
between	regimen	
complexity,	cancer	site,	and	
drug	type	
*Overadherence	seen	in	
20/100		when:	1)	when	
starting/stopping	drug	and	
2)	when	pharmacies	
delivered	medications	prior	
to	start	of	cycle	
*Patients	with	breast	
cancer	were	found	to	have	
greater	rates	of	
overadherence	as	
compared	with	other	sites	
of	cancer	
*As	regimen	complexity	
increased,	as	did	levels	of	
overadherence	
*Of	the	52	patients	with	a	
simple	regimen	
(continuous),	only	1	patient	
was	found	to	be	
overadherent.	
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5	 Perceptions	
and	
experiences	
of	patients	
receiving	oral	
chemotherap
y.	
Simchowitz,	
B;	Shiman	L;	
Spencer	J;	
Brouillard	D;	
Gross	A;	
Connor	M;	
Weingart	SN.	
Clinical	
Journal	of	
Oncology	
Nursing,Aug	
2010;	14(4):	
447-453.	
*Patient	and	
caregiver	survey	
and	focus	group	
*Two	2	hour	focus	
groups-	patients	
were	described	the	
study	and	allowed	
time	for	questions	
prior	to	researchers	
obtaining	consent.		
*Initial	survey	of	
participants	
collected	socio-
demographic	
information	
*During	the	
sessions,	1	
researcher	
facilitated	with	
probing	questions	
while	another	2	
researchers	
observed	and	took	
notes.		
*Sessions	were	
auto-recorded	and	
transcribed	
*Transcripts	of	the	
interviews	as	well	as	
notes	taken	during	
the	sessions	were	
analyzed	and	
grouped	into	major	
and	minor	themes		
*15	past	and	
present	oral	chemo	
patients	and	care-	
givers-	73%	were	
female,	93%	were	
Caucasian,	mean	
age-	56	years	old.	
73%	had	private	
insurance,	13%	had	
Medicaid,	while	7%	
were	covered	by	
Medicare.	Only	1	of	
the	fifteen	
participants	were	
not	currently	being	
prescribed	oral	
chemotherapy	at	
the	time	of	the	
study.	Patients	were	
on	oral	therapies	for	
an	average	of	22	
months.		
*Dana	Farber/		
Harvard	Cancer	
Center	in	Boston,	
MA	
*Socio-
demographic	
information																														
*Two	2	hour	
focus	groups	
led	by	a	
member	of	the	
study	group.																													
*Sessions	had	
open	format	
so	information	
between	the	
two	groups	
varied.		
*Oral	
chemotherapy	
prescribed	
(sunitinib,	
capecitabine,	
mercaptopurin
e,	
temzolomide,	
lapatinib,	and	
imatinib)	
*Selection	bias-
Participants	were	
identified	by	their	
oncologist-	may	
have	been	more	
motivated	and	
knowledgeable	than	
most	patients																				
*Assessed	
adherence	based	on	
self-report;	may	
have	skewed	results																																		
*Participants	only	
from	one	
comprehensive	
cancer	center	
*No	data	collected	
on	disease	type		
*Many	participants	were	
unprepared	to	manage	the	
adverse	effects	of	their	oral	
chemotherapy																																								
*Described	few	issues	
around	adherence-	believe	
due	to	embarrassment	
related	to	admitting	their	
own	errors															
	*Cited	financial	burden	as	
an	issue	as	well	as	finding	
pharmacies that	carried	the	
drug	as	they	are	not	
stocked	at	retail	pharmacies		
*Patients	identified	a	need	
for	improved	patient	
education	surrounding	the	
use	of	oral	chemotherapies	
(including	adverse	effects	as	
well	as	handling	of	the	
drugs)	
*Participants	felt	that	more	
frequent	follow	up	with	
their	providers	would	have	
been	beneficial	
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6	 Feasibility	
Pilot	on	
Medication	
Adherence	
and	
Knowledge	in	
Ambulatory	
Patients	With	
Gastrointestin
al	Cancer.	
Sommers,	
Robin	M.;	
Miller,	
Kathleen;	
Berry,	Donna	
L.:	Oncology	
Nursing	
Forum,	Jul	
2012.	
39(4)373-9.		
Descriptive	study,	
feasibility	pilot	
study	
*Study	team	
included	physicians,	
clinic	nurses,	NPs,	
and	research	
nurses-	all	of	whom	
received	training	on	
screening	for	
eligible	patients	and	
data	collection.		
*Participants	were	
given	written	dosing	
instructions	and	
education	material	
on	their	new	oral	
chemotherapies.	
They	were	also	
given	a	drug	diary	
with	instructions,	
including	to	be	bring	
diary	back	to	first	
appointment	
following	
completion	of	their	
first	cycle	
*72	hours	after	
initiation	of	the	
study,	patients	were	
contacted	to	assess	
understanding	of	
their	medication		
*Following	
completion	of	the	
30	patients	with	GI	
cancer	on	1+	oral	
chemotherapy	
*Convenience	
sample	
*Participants	were	
>18	years	old,	could	
read	and	write	
English,	and	had	
access	to	a	
telephone	
*23	participants	
were	male,	7	were	
female		
*Mean	age	–	53	
years	
Outpatient	
oncology	unit	at	
the	National	
Cancer	Institute	
*Located	within	an	
urban	community	
in	the	northeastern	
US	
*GI	cancer	
patients	only					
*Written	and	
verbal	
education																																		
*Telephone	
contacts													
*Patient	
knowledge													
*Drug	diary																															
*Self-reporting	
of	medication	
adherence	
among	
patients	
*Convenience	
sample-	may	not	be	
representative	of	
majority	patient	
population															
*Able	to	read	and	
write	*English	
speaking	only			
*Those	with	
telephone access																																				
*Only	enrolled	for	
first	cycle-	3-4	
weeks,	may	have	
altered	results	
based	on	short	time	
span																																							
*Possible	
Hawthorne	Effect	
from	self-reporting	
*17	participants	
experienced	adverse	effects	
within	72	hours-	8	of	whom	
unable	to	verbalize	
management	of	symptoms																																										
*7	had	chemotherapy	held	
due	to	medication	toxicities																										
*Most	(n=	21)	were	able	to	
verbalize	1-3	symptoms	of	
chemo, but	few	were	able	
to	verbalize	drug-specific	
adverse	effects	to	report		
*23	patients	verbalized	
increased	satisfaction	with	
72	hour	follow	up	call	to	
assess	understanding	of	
information	and	provide	
clarification	
*MMAS-8	scores	ranged	
among	the	30	participants	
from	5-8	(higher	the	score,	
the	higher	the	level	of	
adherence)		
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first	cycle,	nurses	
reviewed	their	drug	
diary	with	patients	
as	well	as	having	
patients	complete	
the	Morisky	
Medication	
Adherence	Scale	
(MMAS-8)	
questionnaire,	both	
of	which	were	used	
to	assess	adherence	
to	their	medication.		
7	 Evaluation	of	
an	education	
program	to	
facilitate	
patient	
adherence,	
toxicity	
monitoring,	
and	promote	
safety	and	
wellbeing	in	
the	self-
administratio
n	of	oral	
chemotherap
y	in	the	home	
setting:	an	
Australian	
study.	
Griffiths,	Tina:	
Pascoe,	
Elizabeth;	
Two-stage,	mixed	
method	approach		
to	evaluate	a	
patient	education	
program	collecting	
qualitative	and	
quantitative	data	
*Time	1-	Education	
provided	to	patient-	
adapted	MASCC	
evaluation	
questionnaire	(total	
of	13	questions)	
filled	out	by	
patients	
immediately	before	
and	following	
education	being	
provided	
*Patients	also	asked	
to	fill	out	the	
National	
15	
hematology/oncolo
gy	patients		
*Greater	than	the	
age	of	18	without	
formal	exclusion	
criteria	
*Participants	were	
obtained	via	
referrals	from	their	
medical	oncologists	
*Patients	with	
limited	English	were	
accompanied	by	
either	an	
interpreter	or	a	
family	member	who	
was	proficient	in	
English	
*Participants	were	
male	with	a	mean	
age	of	55.75	years,	
Nurse	led	
outpatient	clinic	
during	December	
2012	to	March	213	
*Cancer	
diagnoses																	
*Specific	oral	
chemotherapy																														
*Education	
session	and	
post	education	
program		
*NCCN	
Distress	
Thermometer	
Screening	Tool	
*No	formal	
exclusion	criteria																																		
*Small	sample	size	
limit	ability	to	
generalize	to	other	
populations						
*Limited	time	
frame-	short	time	
span	not	
representative	of	
how	patients	
manage	their	
chemotherapy	over	
a	prolonged	period	
of	time.		
*Those	participants	
with	limited	English-	
not	all	accompanied	
by	a	trained	
interpreter.		
	
*Lack	of	or	limited	patient	
education regarding	PO	
chemotherapy	plays	heavily	
in	patient	adherence																															
*Education	with	complex	
regimens	increased	
adherence		
*100%	reported	improved	
understanding	following	the	
education	program.		
*Distress	Thermometer	
level	decreased	from	initial	
interaction	following	
education	to	follow	up	the	
next	week	from	3.8/10	
down	to	2.3/10	
*All	patients	within	the	
study	reported	the	written	
take	home	materials	to	be	
the	most	beneficial	in	
conjunction	with	the	verbal	
reinforcement.		
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Australian	
Journal	of	
Cancer	
Nursing.	Nov	
2014;	15(2):	
30-38.	
Comprehensive	
Cancer	Network	
(NCCN)	Distress	
Thermometer	
Screening	Tool	to	
assess	patients	
potential	stress	
levels.		
*Patients	given	
written	instructions	
which	included-	
drug	specific	
information,	
adverse	effects,	
food	and	drug	
interactions,	when	
to	contact	their	
provider,	and	
special	precautions	
associated	with	
their	medications.	
*Time	2-	Took	place	
1	week	following	
education	session.	
Assessment	of	
efficacy	of	initial	
session	conducted	
via	telephone	call	
from	nurse.	NCCN	
Distress	
Thermometer	
Screening	Tool	
completed	and	
additional	support	
provided	to	patient	
7	were	female	with	
a	mean	age	of	
58.28.	
*Participants	reported	they	
felt	that	the	increased	
education	assisted	with	
increased	adherence	as	
they	knew	better	how	to	
manage	their	adverse	
effects,	when	to	take	their	
medications,	and	when	to	
call	their	providers.		
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as	needed	by	nurse.	
8	 Current	
nursing	
practice	for	
patients	on	
oral	
chemotherap
y:	a	
multicenter	
survey	in	
Japan.	
Komatsu	H;	
Yagasaki	K;	
Yoshimura	
K.BMC	
Research	
Notes.	2014	
Apr	23:	Vol.	7,	
pp	529.																																		
Two	self-	reported	
surveys	were	
distributed	to	309	
cancer	centers	and	
141	large	hospitals	
in	Japan.		
*The	first	survey	
was	directed	
towards	nurse-	
assessed	staffing,	
nursing	
demographics	and	
experience	and	was	
40	questions.	
*The	second	survey	
was	patient	based	
including	10	
additional	
questions.	Assessed	
information	on	
patient	
demographics	and	
adherence.	
*Multivariate	
logistic	regression	
was	utilized	to	
identify	elements	
surrounding	
adherence	related	
practices	in	nursing.		
62	RNs	from	62	
hospitals	were	
consented	to	
participate	in	both	
surveys	including	
the	patient	based	
which	looked	at	249	
patients	on	oral		
chemotherapy	
*Average	age	of	
participants-	41.5	
years	
*Average	nursing	-	
19.4,	and	
chemotherapy	
experience	11.6	
years.	
*72.6%	were	
oncology	nurse	
certified.		
Designated	cancer	
centers	and	large	
general	hospitals	in	
Japan	
*Utilized	both	
cancer	centers	
and	hospital	
based	
ambulatory	
cancer	centers																																												
*Size	of	
facilities	which	
participated	
*Patient	based	
survey	answered	by	
RNs	not	patients																															
*Looks	only	at	
nursing	practices	
related	to
adherence		
*Nursing	practices	
surrounding	oral	chemo	
varied greatly	around	the	
country																																														
*Few	offered	system	
specific	needs/education																																			
*Increased	adherence	
found	related	to	RN	
background,	treatment	
type,	and	healthcare	system	
related	factors																								
*RNs	found	rarely	to	inquire	
how	patients	understood	
therapy,	how	they	managed	
their	meds	at	home,	or	level	
of	confidence	of	
administration	
*Only	64.5%	of	patients	
reported	understanding	of	
their	medication	schedules	
and	58.1%	of	their	
medications		
*20%	of	nurses	were	
unclear	as	to	their	role	in	
monitoring	and	educating	
patients	on	oral	
chemotherapy,	30.6%	
assessed	patient	confidence	
in	taking	their	medications.	
*Nurses	were	less	likely	to	
ask	questions	related	to	
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patient	adherence	of	
patients	who	were	refilling	
their	medications	as	
compared	with	those	being	
given	new	prescriptions.		
9	 Putting	
Evidence	Into	
Practice:	
Evidence-
Based	
Interventions	
for	Oral	
Agents	for	
Cancer.	
Spoelstra,	
Sandra	L.;	
Sansoucie,	
Holly:	Clinical	
Journal	of	
Oncology	
Nursing,	June	
2015:	19(3):	
60-72.	
Systematic	review	
*Search	of	PubMed	
and	CINAHL	
*Search	terms-	
medication	
adherence,	patient	
compliance,	oral	
chemotherapy,	anti-
neoplastic,	
nonadherence	
*Study	types	
included	systematic	
reviews,	practice	
guidelines,	meta-
analyses,	and	
clinical	research	
*Interventions	were	
broken	up	into	
levels	of	evidence:	
“recommended	for	
practice”,	“likely	to	
be	effective”,	
“effectiveness	not	
found”,	“benefits	
balanced	with	
harms”	and	“not	
recommended	for	
practice”	
131	studies	
*Initial	search	
yielded	25,478	
articles,	after	
utilizing	inclusion	
and	exclusion	
criteria	and	removal	
of	duplicates,	a	total	
of	131	articles	were	
utilized	for	the	
study.	
N/A	 *Interventions	
to	increase	
adherence															
*Included	in	their	
study,	articles	of	
patients	outside	of	
hematology/oncolo
gy	population																										
*Primarily	
intervention	based		
*Small	sample	sizes	
of	several	studies	
examined	
*Majority	of	research	was	
found	in	noncancerous	
conditions-	found	a	need	
for	further	research		
*Lack	of	patient	education	
and	feedback	greatly	
contribute	to	nonadherence																																							
*Adverse	effects	limited	
adherence																																															
*High	rate	of	depression	in	
patients	with	chronic	
disease	can	affect	
adherence		
*Found	the	highest	number	
of	studies	to	support	multi-
component	interventions-	
i.e.-	a	combination	of	
interventions	to	increase	
adherence,	shown	to	
significantly	increase	
adherence	to	oral	
chemotherapy	
*Most	interventions	that	
addressed	adherence	were	
targeting	management	of	
adverse	effects-	not	
education	to	decrease	or	
prevent	them	
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	 *“Likely	to	be	effective”	in	
increasing	adherence-	text	
messages,	automated	voice	
response,	and	treatment	of	
depression	
1
0	
Adherence	
enhancing	
interventions	
for	oral	
anticancer	
agents:	a	
systematic	
review.	
Mathes,	Tim;	
Antoine,	
Sunya-Lee;	
Pieper,	David;	
Eikermann,	
Michaela;	
Cancer	
Treatment	
Reviews,	Feb	
2014;	40(1):	
102-108.	
Systematic	review	
*Search	conducted	
in	Medline	and	
Embase	
*Inclusion	criteria-	
Patients	with	
diagnosis	of	cancer,	
tanking	oral	
chemotherapy,	>16	
years	old,	assessed	
adherence,	either	in	
German	or	English,	
controlled	studies,	
interventions	to	
increase	adherence		
*Quality	of	studies	
were	assessed	via	
National	Institute	
for	Health	Clinical	
Excellence	(NICE)	
tool	for	cohort	
studies,	for		
randomized	control	
trials	(RCT)	the	
Cochrane	Effective	
Practice	and	
Organization	of	Care	
Group	tool	was	
utilized.		
Initial	search	yielded	
2309	articles	
*After	application	of	
inclusion	criteria	
and	removal	of	
duplicates,	a	total	of	
6	articles	were	
utilized	for	the	
study	
N/A	 *Barriers	to	
adherence	to	
oral	
chemotherapy																
*Monitoring	
patients	for	
adherence		
*Limited	sample	
size						
*Low	
methodological	
study	quality-	most	
rated	moderate	to	
low	on	study	quality	
*Did	not	limit	
publication	date	
*Education	main	barrier	
assessed	with	interventions																															
*Forgetfulness-	several	
studies	looked	at	reminders	
for	patients	
*Found	that	interventions	
focusing	on	education	were	
most	advantageous	in	
decreasing	nonadherence	
as	it	addresses	several	
causes	of	poor	adherence	
of	oral	chemotherapy.		
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1
1	
Essentials	for	
Oral	
Oncolytics:	
Developing	a	
Nursing	
Reference.	
Matthews,	
Jennifer;	
Caprera,	
Patricia	
Holland;	
Clinical	
Journal	of	
Oncology	
Nursing,	Oct	
2014;	18(5):	
E88-92.		
17	educational	in-
service	programs	for	
oncology	staff	
between	September	
2011	and	February	
2013.		
*Roundtable	
discussion	groups	
were	conducted	
prior	to	the	in-
service	assessing	
the	challenges	of	
maintaining	
adherence	in	
patients	on	oral	
chemotherapy	
*Participants	were	
surveyed	of	their	
policies	and	
procedures	for	
education	of	
patients	prescribed	
oral	chemotherapy,	
what	resources	
were	available	for	
education,	and	their	
confidence	level	in	
their	ability	to	
provide	education	
to	patients.		
*Participants	were	
also	surveyed	on	
their	standards	for	
documentation,	
what	type	of	
200	RNs,	APRNs,	
pharmacy	industry	
consultants,	and	
pharmacists		
Inpatient	and	
outpatient	facilities	
across	the	US	
including	major	
cancer	centers	in	
Boston,	MA,	free-
standing	
hematology/oncol
ogy	offices,	private	
offices,	hospital	
affiliated	cancer	
centers,	inpatient	
oncology	units,	
and	cancer	centers	
with	several	
different	clinical	
sites.		
*Position	of	
staff	involved	
in	educational	
in-service		
*Poor	
documentation	of	
methodology	
techniques		
*Education	from	staff	to	
patients	varies	heavily-	
often	lacking												
*Poor	education	attributed	
to	time	constraints	for	
teaching	and	follow	up	from	
clinicians	as	well	as	limited	
experience	with	the	drugs	
being	given																									
*Lack	of	or	decreased	
follow	up	with	patient	for	
assessment													
*Lack	of	individualization	of	
plan	of	care	for	patients	
including	drug	specific	
adverse	effects,	laboratory	
monitoring,	and	toxicity	
monitoring	lead	to	poor	
patient	outcomes	and	
decreased	adherence.	
*Participants	felt	that	lack	
of	time	limited	ability	to	
assess	patient’s	
understanding	of	their	
medications,	time	to	
answer	questions,	and	
assess	risk	for	poor	
adherence	in	many	patients	
leading	to	poor	patient	
outcomes	and	adherence.	
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charting	system	
they	utilized,	and	
follow	up	with	
patients	to	monitor	
oral	adherence.		
1
2	
The	role	of	
the	nurse	in	
patient	
education	
and	follow	up	
of	people	
receiving	oral	
anti-cancer	
treatment:	an	
Australian	
survey.	
Johnson,	
Catherine;	
Adler,	Kim;	
Australian	
Journal	of	
Cancer	
Nursing.	Jun	
2014;	15(1):	
4-12.	
Cross-	sectional	
survey	
*Invitation	to	
participate	in	the	
study	were	
distributed	
nationwide	via	
email	to	members	
of	the	Cancer	
Nurses	Society	of	
Australia	(CNSA)		
*Survey	consisted	of	
a	20	multiple	choice	
and	open	ended	
questionnaire		
*A	follow	up	email	
was	sent	to	follow	
up	two	weeks	
following	the	initial	
email	invitation.		
*Results	of	the	
survey	were	
compared	with	the	
Multinational	
Association	for	
Supportive	Care	in	
Cancer	(MASCC)	
survey	which	was	
performed	in	2006.	
182	survey	
responses	from	RNs	
who	were	members	
of	Cancer	Nurses	
Society	of	Australia	
*Participants	were	
anonymous	
*Researchers	did	
not	have	direct	
access	to	
participants.		
*Most	participants	
reports	>	16	years	
experience	in	
oncology	nursing	
*28%	were	bachelor	
prepared	
*21%	were	
oncology	certified	
	
Email	surveys	of	
RNs	across	
Australia	
*Role	of	RN	in	
patient	
education																																		
*Follow	up	of	
patients	taking	
oral	
chemotherapy	
*Low	%	of	
responses	of	RNs																																																																
*Snowball	sampling	
*30%	reported	lack	of	time	
for education 																				
*RN	education	of	oral	
chemotherapy	lacking																									
*20%	reported	difficulty	
with	safety	issues	and	29%	
related	to	adverse	effect	
management												
	*RN	respondents	
suggested	need	for	formal	
education	to	patients	and	
protocols	on	follow	up	to	
increase	adherence		
*All	respondents	reported	
working	with	on	average	7	
of	the	22	oral	
chemotherapy	drugs	in	the	
survey	as	well	as	
investigational	and	research	
medications.	Indicates	a	
potential	lack	of	education	
regarding	a	majority	of	
other	medications	that	
patients	may	be	prescribed.	
It	also	indicates	the	rapid	
evolution	of	medication	
available	to	patients	that	
staff	need	to	be	aware	of.	
*Staff	who	worked	in	the	
inpatient	setting	reported	
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lack	of	education	regarding	
oral	chemotherapy	agents	
*When	compared	with	the	
MASCC	survey,	there	was	a	
great	increase	over	the	
seven	year	span	in	the	
education	and	follow	
directed	to	patients	on	oral	
chemotherapy.	
Additionally,	39%	of	nurses	
reported	that	patient	
education	was	provided	by	
prescribing	physicians	
which	was	double	the	rate	
from	the	MASCC	survey.		
*20%	of	nurses	reported	
not	having	enough	time	to	
provide	education,	30%	
reported	a	knowledge	
deficit	regarding	oral	
chemotherapy	agents.	
*The	number	of	nurses	who	
reported	policies	and	
guidelines	in	place	for	the	
management	of	oral	agents	
only	increased	slightly	from	
the	MASCC	survey	from	
64.5%	to	71%	despite	the	
increasing	use	of	these	
medications	
*Nurses	requested	
formalized	education	on	
oral	therapies	similar	to	
those	of	intravenous	
chemotherapy.		
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1
3	
Treatment	
With	Oral	
Anticancer	
Agents:	
Symptom	
Severity	and	
Attribution,	
and	
Interference	
With	
Comorbid	
Management.	
Spoelstra,	
Sandra	L;	
Given,	
Charles	W;	
Sikorskii,	Alla;	
Majumder,	
Atreyee;	
Schueller,	
Monica;	
Given,	
Barbara	A;	
Oncology	
Nursing	
Forum.	Jan	
2015;	42(1):	
80-88.	
Descriptive	
exploratory	study	to	
assess	the	severity	
and	occurrence	of	
adverse	effects	in	
affecting	the	
adherence	rates	of	
patients	being	
prescribed	oral	
chemotherapies.		
*Conducted	over	an	
8	week	time	span	
*Total	of	five	
telephone	
interviews	were	
conducted	on	
patients	being	
prescribed	oral	
therapies	
*Data	was	entered	
in	the	PROMIS	
Assessment	Center	
Data	Collection	
Platform	
*At	each	interview	
symptoms	were	
assessed	utilizing	
the	Symptom	
Experience	
Inventory.	If	
symptoms	were	
reported,	they	were	
asked	to	rate	them	
on	a	scale	to	1-10	
with	10	being	the	
34	patients	were	
initially	approached	
for	participation	in	
the	study	as	a	
convenience	sample	
*3	reported	not	
being	interested	
and	another	did	not	
have	the	time	to	
participate	
*A	total	of	30	adult	
patients	consented		
*Only	28	completed	
all	five	telephone	
interviews.		
*Mean	age-	65.1	
years	
*Most	site	of	
cancer-	colorectal	
(n=	10)	
*21	had	late	stage	
cancer	
1	comprehensive	
cancer	center	and	
2	community	
based	oncology	
programs	in	the	US	
*Symptoms																														
*Comorbid	
conditions	
*Utilized	
convenience	sample																																		
*Self-reporting	of	
adherence																											
*Small	sample	size	
	
*Most	patients	reported	
that	they	at least	2	
comorbid	conditions	
increased	effects	from	oral	
chemotherapy																																									
*Most	patients	included	
had	complex	regimens	
which	often	included	IV	
chemotherapy-	regimen	
complexity	found	to	have	
no	statistical	significance.			
*Of	the	23	patients	with	
comorbid	conditions,	all	
reported	that	the	
management	of	their	
cancer	interfered	with	their	
ability	to	manage	their	
comorbidities.		
*Fatigue	was	the	most	
common	adverse	effect	
reported	by	patients.	Other	
symptoms	commonly	
reported	>50%	of	
interviews	included	
numbness	and	tingling	and	
sleep	disturbances.	33%	of	
patients	reported-	diarrhea,	
pain,	swelling	of	the	
extremities,	poor	appetite,	
rashes,	and	shortness	of	
breath.	Patients	expressed	
that	symptoms	affected	
their	ability	to	take	their	
medications	often.	
*27	patients	reported	being	
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worst.		
*Adherence	rates	
were	assessed	via	
self-report	as	a	yes	
or	no	at	each	
interview.	
adherent	100%	of	the	time.	
Of	the	three	who	reported	
nonadherence-	one	stated	
that	she	stopped	her	
medication	for	3	weeks	for	
vacation	as	she	did	not	wish	
to	experience	adverse	
effects,	one	was	due	to	the	
fact	that	her	medication	
had	not	come	in	the	mail,	
and	the	third	did	not	
provide	a	reason	to	
researchers.		
*Researchers	felt	that	
results	of	treatment	
provided	strong	evidence	to	
support	that	increased	rates	
of	adverse	effects	
interfered	with	patient’s	
ability	to	manage	their	oral	
chemotherapies	and	
decreased	adherence.		
1
4	
Determinants	
and	
associated	
factors	
influencing	
medication	
adherence	
and	
persistence	to	
oral	
anticancer	
drugs:	A	
systematic	
Systematic	review	
*Literature	search	
conducted	in	
PubMed,	Cochrane	
database,	Web	of	
Science,	and	CINAHL	
*Inclusion	criteria-	
looked	only	at	oral	
chemotherapy,	
assessed	factors	
related	to	
adherence	or	
compliance	of	oral	
*Original	search	of	
the	literature	
yielded	3,351	
articles	
*After	elimination	
of	duplicates,	and	
consideration	of	
inclusion	and	
exclusion	criteria-	
25	articles	were	
utilized	for	the	
study	
N/A	 *Search	
engines	
selected					
*Quality	of	
research	
obtained	
*Most	patients	
within	studies	found	
were	breast	cancer	
patients-	may	not	
be	generalize	to	
other	populations																								
*Scarce	findings	
with	other	oncology	
populations-	
requires	additional	
research									
*Potential	conflict	
of	interest	with	
*Treatment	related	side	
effects	were	most	
frequently	reported	reason	
for	non-adherence	
*Longer	duration	of	
treatment	also	led	to	
decreased	adherence	rates																
*Most	common	reason	for	
unintentional	
noncompliance:	forgetting	a	
dose;	most	common	reason	
for	intentional:	decreased	
perceived	efficacy	of	
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review.	
Verbrugghe,	
M;	
Verhaeghe,	S;	
Lauwaert,	K;	
Beeckman,	D;	
Van	Hecke,	A:	
Cancer	
Treatment	
Reviews,	Oct	
2013;	39(6):	
610-621.	
therapies,	subjects	
>18	years	old,	
research	with	either	
a	strong	or	
moderate	
methodological	
quality	
*Search	terms	
included:	
medication	
adherence,	patient	
compliance,	
antineoplastic	
agents,	neoplasms,	
tumor,	cancer,	
patient	adherence	
*Searched	material	
from	between	1990-
2012	in	either	
English,	German,	or	
Dutch	
*Excluded	research	
conducted	in	
developing	
countries	as	the	
healthcare	systems	
are	so	greatly	
different	from	
developed.	
*Methodological	
quality	was	
reviewed	
independently	by	
two	reviewers	while	
utilizing	the	Quality	
some	studies	as	
were	performed	by	
commercial	or	
pharmaceutical	
grants		
*Wide	variation	
noted	among	the	
definitions	of	
adherence-	varied	
from	<80%	to	
<100%	for	
nonadherence,	
>110%	for	
overadherence.	
treatment,	or	no	added	
benefit	from	medication																										
*Lack	of	follow	up	
appointments	and	short	
visit	times																												
*Poor	patient	and	family	
education																																																	
*Socioeconomic	status-	
Copay	of	≥$30	can	be	
barrier	to	obtaining	
medication	
*Mixed	results	in	how	
presence	of	polypharmacy	
as	well	as	comorbidities	
affect	adherence.	Some	
studies	have	shown	these	
increase	adherence	while	
others	have	shown	the	
opposite.		
*Age	≤45	and	≥85	were	
found	to	have	increased	risk	
for	nonadherence	(n=	9)	
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Assessment	Tool	for	
quantitative	studies,	
the	Critical	
Appraisal	Skills	
Programme	(CASP)	
which	looked	at	
quantitative	studies.		
1
5	
Exploring	
chronic	
myeloid	
leukemia	
patients’'	
reasons	for	
not	adhering	
to	the	oral	
anticancer	
drug	imatinib	
as	prescribed.	
Eliasson,	L;	
Clifford	S;	
Barber	N;	
Marin	D;	
Leukemia	
Research.	
May	2011;	
Vol.	35(5),	
626-30.	
Qualitative	study	
*Researchers	
outfitted	patient’s	
medication	bottles	
with	an	electronic	
device	that	
monitored	the	date	
and	time	each	time	
the	bottle	was	
opened	and	closed.		
*Measurement	
occurred	over	a	3	
month	period.	
*Researchers	
defined	
nonadherence	as	
adherence	rate	
≤90%.	This	rate	was	
chosen	based	on	
common	adherence	
rate	from	similar	
studies.		
*Adherence	was	
also	assessed	via	
self-reporting	
*Interviews	were	
recorded	and	
transcribed	then	
21	Chronic	Myeloid	
Leukemia	(CML)	
patients	on	imatinib	
for	≥2	years.	
	
Outpatient	CML	
clinics	located	in	a	
teaching	hospital	
in	the	United	
Kingdom	
*Self	report	of	
adherence		
*Participants	
recruited	from	
previous	
related	study-	
selected	4	
nonadherent	
patients	for	
every	one	
adherent			
*Looked	only	at	
patients	on	imatinib		
with	CML-	may	not	
be	generalized	to	
other	oncology	
populations					
	*Self-report	of	
adherence-	possible	
Hawthorne	Effect	
*Some	funding	was	
obtained	by	
researchers	from	
Novartis	
*2	researchers	
declared	affiliation	
with	Novartis	
and/or	Bristol	
Myers	Squibb	
*Unintentional	causes	
included:	forgetfulness	
(n=13),	could	not	obtain	
medication	from	pharmacy	
(n=1),	and	unintentional	
overdosing																																			
*Intentional	nonadherence	
(n=10)-	Most	commonly	
reported	was	adverse	
effects	of	treatment-	
nausea,	fatigue.																																																					
*12:21	were	not	aware	of	
the	clinical	consequences	of	
missing	a	dose		and	did	not	
feel	this	would	affect	their	
clinical	response	to	
treatment		
*A	total	of	14%	of	
participants	were	
nonadherent.	
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analyzed	via	
quantitative	data	
analysis	software.	
Meta-categories	
were	identified	
from	transcripts.		
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Appendix G 
Critical	Appraisal	for	Summaries	of	Evidence	(CASE)	Worksheet	
*Numbers	in	evaluation	correspond	with	those	assigned	to	articles	in	data	extrapolation	chart*	
Questions	 Evaluation	
Summary	Topic	
1. Is	the	summary	specific	in	scope	and	
application?	
Yes-	1,	2,	3,	4,	5,	6,	7,	8,	9,	10,	11,	12,	13,	14,	
15	
Not	completely-	
No-	
Summary	Methods	
2. Is	the	authorship	of	the	summary	
transparent?	
Yes-	1,	2,	3,	4,	5,	6,	7,	8,	9,	10,	11,	12,	13,	14,	
15	
Not	completely-	
No-	
3. Are	the	reviewer(s)/editor(s)	of	the	
summary	transparent?	
Yes-	1,	2,	3,	4,	5,	7,	9,	10,	11,	14,	15	
Not	completely-	6,	8,	12,	13	
No-	7	
4. Are	the	research	methods	transparent	
and	comprehensive?	
Yes-	1,	2,	3,	4,	5,	6,	7,	8,	9,	10,	11,	12,	13,	14,	
15	
Not	completely-		
No-	
5. Is	the	evidence	grading	system	
transparent	and	translatable?		
Yes-	1,	2,	3,	4,	5,	6,	7,	8,	9,	10,	11,	13,	14,	15	
Not	completely-	12	
No-	
Summary	Content	
6. Are	the	recommendations	clear?	 Yes-	1,	2,	3,	4,	6,	7,	8,	9,	11,	12,	13,	14	
Not	completely-	5,	10	
No-	15	
7. Are	the	recommendations	
appropriately	cited?	
Yes-	1,	2,	3,	4,	5,	6,	7,	9,	11,	12,	13,	14	
Not	completely-	8,	10	
No-	15	
8. Are	the	recommendations	current?	 Yes-	1,	2,	3,	4,	5,	6,	7,	8,	9,	10,	11,	12,	13,	14,	
15	
Not	completely-	
No-	
9. Is	the	summary	unbiased?	 Yes-	1,	2,	3,	4,	5,	6,	7,	8,	9,	10,	12,	13,	14,	15	
Not	completely-	
No-	
Summary	Application		
10. Can	this	summary	be	applied	to	your	
patient(s)?	
Yes-	1,	2,	3,	4,	5,	6,	7,	8,	9,	10,	11,	12,	13,	14,	
15	
Not	completely-	
No-	
 
